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Contribution of the Unfolded Protein Response to VEGF Expression
Abstract
Tumor cells experience a limiting microenvironment due to inadequate vascularization that can affect the
normal functioning of intracellular organelles. In the case of the endoplasmic reticulum, the limiting
environment is further exacerbated by the high metabolic demands of the tumor cells, which together
interfere with the proper maturation of nascent proteins synthesized there. The resultant accumulation of
unfolded proteins activates a signal transduction pathway known as the Unfolded Protein Response,
which serves primarily to protect the cell during stress and helps restore homeostasis to this organelle.
As tumors expand resulting in regions that are a greater distance from functional blood vessels, they
become increasingly hypoxic, which ultimately results in the activation of another stress pathway that is
primarily regulated by the hypoxia inducible factor family of transcription factors (HIFs). This pathway
protects cancer cells, in part, by up-regulating VEGFA, which stimulates blood flow to the tumor in a
process known as angiogenesis. The interplay between these two stress pathways in tumor cell survival
is relatively unexplored.
Microarray analysis of the unfolded protein response in a human medulloblastoma cell line revealed that,
in addition to known targets, a large number of proangiogenic factors were upregulated. Real-Time PCR
analyses confirmed that four of these factors, VEGFA, FGF2, angiogenin and IL8, were transcriptionally upregulated in multiple cell lines by various ER stress inducers. Our studies on VEGFA regulation revealed
that ATF4, a UPR-inducible transcription factor, bound to the mouse and human VEGFA promoters. Using
a combination of mouse embryonic fibroblasts and human neuroblastoma cell lines that are deficient in
this transcription factor, we demonstrated that ATF4 binds to the VEGFA promoter and contributes
significantly to VEGFA expression in response to ER stress. We also found that VEGFA mRNA stability is
increased in response to UPR activation, via activation of AMP kinase, demonstrating that increased
mRNA levels occur at two regulatory points. In keeping with the increased mRNA levels, we found that
VEGFA protein is secreted at levels as high as or higher than that achieved in response to hypoxia.
Because the inadequate microenvironment experienced by solid tumors is expected to activate both UPR
and HIF signaling pathways, we tested for possible interaction between them. Our studies show that
VEGFA transcription rate and secreted protein levels are induced to a greater extent when both of these
pathways are activated together as compared to each stress alone. Although we demonstrated a synergy
between the two stress pathways experienced by tumor cells, surprisingly we found that this was not
through the combined effects of the two different transcription factors, but instead that UPR activation
can enhance HIF signaling, which has implications for other HIF targets that aid in tumor survival.
Our results indicate that the UPR plays a significant role in inducing positive regulators of angiogenesis. In
the case of VEGFA expression this occurs at transcriptional, posttranscriptional and post-translational
levels and is likely to have widespread implications for promoting angiogenesis in response to normal
physiological cues as well as in pathological conditions like cancer.
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ABSTRACT
Tumor cells experience a limiting microenvironment due to inadequate
vascularization that can affect the normal functioning of intracellular organelles. In the
case of the endoplasmic reticulum, the limiting environment is further exacerbated by the
high metabolic demands of the tumor cells, which together interfere with the proper
maturation of nascent proteins synthesized there. The resultant accumulation of unfolded
proteins activates a signal transduction pathway known as the Unfolded Protein
Response, which serves primarily to protect the cell during stress and helps restore
homeostasis to this organelle. As tumors expand resulting in regions that are a greater
distance from functional blood vessels, they become increasingly hypoxic, which
ultimately results in the activation of another stress pathway that is primarily regulated by
the hypoxia inducible factor family of transcription factors (HIFs). This pathway protects
cancer cells, in part, by up-regulating VEGFA, which stimulates blood flow to the tumor
in a process known as angiogenesis. The interplay between these two stress pathways in
tumor cell survival is relatively unexplored.
Microarray analysis of the unfolded protein response in a human medulloblastoma
cell line revealed that, in addition to known targets, a large number of proangiogenic
factors were up-regulated. Real-Time PCR analyses confirmed that four of these factors,
VEGFA, FGF2, angiogenin and IL8, were transcriptionally up-regulated in multiple cell
lines by various ER stress inducers. Our studies on VEGFA regulation revealed that
ATF4, a UPR-inducible transcription factor, bound to the mouse and human VEGFA
promoters. Using a combination of mouse embryonic fibroblasts and human
neuroblastoma cell lines that are deficient in this transcription factor, we demonstrated
that ATF4 binds to the VEGFA promoter and contributes significantly to VEGFA
expression in response to ER stress. We also found that VEGFA mRNA stability is
increased in response to UPR activation, via activation of AMP kinase, demonstrating
that increased mRNA levels occur at two regulatory points. In keeping with the
increased mRNA levels, we found that VEGFA protein is secreted at levels as high as or
higher than that achieved in response to hypoxia. Because the inadequate
microenvironment experienced by solid tumors is expected to activate both UPR and HIF
signaling pathways, we tested for possible interaction between them. Our studies show
that VEGFA transcription rate and secreted protein levels are induced to a greater extent
when both of these pathways are activated together as compared to each stress alone.
Although we demonstrated a synergy between the two stress pathways experienced by
tumor cells, surprisingly we found that this was not through the combined effects of the
two different transcription factors, but instead that UPR activation can enhance HIF
signaling, which has implications for other HIF targets that aid in tumor survival.
Our results indicate that the UPR plays a significant role in inducing positive
regulators of angiogenesis. In the case of VEGFA expression this occurs at
transcriptional, post-transcriptional and post-translational levels and is likely to have
widespread implications for promoting angiogenesis in response to normal physiological
cues as well as in pathological conditions like cancer.
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CHAPTER 1.

INTRODUCTION1

Angiogenesis
The continued synthesis, sprouting and migration of blood vessels from preexisting ones and remodeling of the vasculature is known as angiogenesis [1]. This
process is required for normal development and homeostasis in a healthy organism. The
complex network of tubular structures consisting of blood and lymphatic vessels that
make up the vascular system are formed primarily by endothelial cells and serve to
transport oxygen, nutrients, and cell signaling molecules between various tissues and
organs in vertebrates. In addition to its role in normal physiology, increased angiogenesis
contributes to the progression of several pathological conditions including cancer,
macular degeneration, cardiac and inflammatory diseases [1]. Alternatively, the
malformation or dysfunction of the vasculature can result in decreased blood supply to
tissues causing ischemia [2]. Thus, a fine balance between proangiogenic factors that
promote endothelial cell growth and antiangiogenic factors that limit it must be achieved
to maintain a normal, functioning vasculature. Understanding the mechanisms by which
this balance is maintained during normal physiology or how it is disrupted in disease
conditions has been the focus of a large number of studies in recent years. [3]
Proangiogenic factors including vascular endothelial growth factor (VEGF),
fibroblast growth factors (FGFs), platelet derived growth factors (PDGFs), and IL8 are
released by cells experiencing inadequate oxygen and nutrient supplies. These
proangiogenic factors act as ligands that bind to specific receptors on endothelial cells
causing them to release matrix metalloproteinases that degrade the extracellular matrix,
which allows the endothelial cells to migrate toward the angiogenic stimulus and to
proliferate in order to establish new blood vessels [4]. The predominant and best-studied
proangiogenic factor is VEGFA, a homodimeric heparin binding glycoprotein that is
produced in several isoforms due to alternative splicing (Figure 1-1). All VEGF isoforms
are synthesized and processed in the endoplasmic reticulum (ER) and transported through
the secretory pathway [5]. There are five different splice variants of the human VEGFA
gene (206, 189, 165, 145 and 121) that have identical N-termini, including an ER
targeting sequence, but different properties due to the inclusion of various exons at their
C-termini that encode the ability to bind heparin and heparin-sulfate containing proteins.
This is an important property that distinguishes the isoforms from each other as it impacts
their ability to diffuse away from the cells or become associated with the extracellular
matrix (ECM). As shown in Figure 1-1 the heparin-binding region for VEGFA is largely
encoded by exons 6 and 7. Most cell types produce several VEGF isoforms
simultaneously, although, 121, 165 and 189 are the predominant ones. VEGF145 has
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Parts of this chapter were adapted with permission. Pereira, E., Preston, A. and
Hendershot, L.M., UPR Activation in Cancer Cells: A Double-Edged Sword, in
Endoplasmic Reticulum Stress in Health and Disease, 2012, Springer. In press [3].
1

Figure 1-1. Gene structure of human VEGFA. (A) VEGFA spans 16,272 bp of chromosome 6p12 and consists of eight
exons. (B) Alternate 5' and 3' splice sites in exons 6, 7 and 8 generate multiple isoforms (C) Table indicating if the various
VEGF isoforms can bind heparin or not. Adapted with permission. Nowak, D.G., J. Woolard, E.M. Amin, O. Konopatskaya,
M.A. Saleem, A.J. Churchill, M.R. Ladomery, S.J. Harper, and D.O. Bates, 2008. Expression of pro- and anti-angiogenic
isoforms of VEGF is differentially regulated by splicing and growth factors. Journal of cell science. 121: 3487-95 [6].
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restricted expression, and is produced mainly by cells derived from reproductive organs.
There are two receptor tyrosine kinases (RTKs), VEGFR1 and VEGFR2 that can bind
VEGFA on their immunoglobulin-like extracellular domains. Early studies identified
VEGF binding to its receptors located on endothelial cells in vitro and in vivo, however,
it is now clear that VEGF receptors are also found on bone marrow derived cells. The
function of VEGFR1 signaling depends on the developmental stage of the animal and the
cell type. Some of the functions of VEGFR1 signaling are to regulate monocyte and
macrophage migration, induce expression of MMP9 thus facilitating tumor metastases
and release growth factors like IL6. VEGFR1 can occur as an alternatively spliced,
soluble form that negatively regulates the activation and signaling of VEGFR2. Soluble
VEGFR1 can preferentially bind to VEGFA and thus act as a ‘trap’ and reduce the
accessibility of VEGFA to bind to VEGFR2. VEGFR1 knockout animals are embryonic
lethal at E8.5-9.0 due to increased hemangioblast and vascular disorganization. VEGFR2
signaling is very important in mediating mitogenic, angiogenic and permeability
enhancing effects of VEGF. VEGFR2 signaling plays an important role in developmental
angiogenesis, vasculogenesis and hematopoiesis. VEGFR2 knockout animals are also
embryonic lethal at E8.5-9.5 due to defective blood-island formation and vasculogenesis
[7].
Regulation of VEGF Expression
The HIF (hypoxia inducible factor) pathway is the best-characterized cellular
stress pathway that leads to the up-regulation of proangiogenic factors in response to
inadequate oxygen delivery [8]. Transcriptional responses to hypoxia are largely
regulated by HIF, a heterodimeric protein composed of an oxygen-labile  subunit and a
constitutively expressed  subunit [9]. There are two  subunit members, HIF1 and
HIF2, which are continuously synthesized and rapidly degraded under normal
physiological conditions. The oxygen-dependent degradation of the HIF--subunit is
mediated by hydroxylation of proline 402 and proline 564 by prolyl hydroxylase domain
protein 2 [10]. Hydroxylated HIF- binds to von Hippel Lindau tumor suppressor protein
(VHL), which then interacts with the protein elongin C and recruits the E3
ubiquitin-protein ligase complex and targets the α subunit for degradation via the 26S
proteasome [11]. In addition, hydroxylation of asparagine 803 inhibits the interaction of
the  subunit with its transcriptional co-activators p300 and CREB binding protein [12].
However, when oxygen supplies are reduced, the activity of the hydroxylase is inhibited.
As a result, the  subunit is not hydrolylated, does not bind VHL, and is stabilized. This
allows it to dimerize with the  subunit and its co-activators, and the resulting complex
(HIF-1 or HIF-2) binds to hypoxia-responsive elements (HRE) on the 5’ flanking region
of target genes like VEGF and increases its transcription [13]. In addition to the HIF
pathway playing an essential role in some normal physiological processes like
development of the embryo and erythropoiesis, there is also a vast amount of data
demonstrating that it contributes to a number of disease states like cancer, ischemia and
inflammation [13].
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In addition to hypoxia leading to a HIF-dependent transcriptional up-regulation of
VEGF, there are data demonstrating that the VEGF transcript can be stabilized by
hypoxia [14]. This post-transcriptional mechanism of inducing VEGF mRNA is due to a
hypoxia-induced protein complex bound to the VEGF 3’-UTR that mediates increased
stability. Other HIF-independent post-transcriptional mechanisms for increasing VEGF
expression have been reported. There are data showing that the stress inducible ER
chaperone ORP150/GRP170 plays a role in post-translational processing/secretion of
VEGFA [15]. Ectopic expression of ORP150 in C6, rat glioma cells, increased VEGFA
secretion, whereas decreasing ORP150 levels with an antisense construct resulted in the
retention of VEGFA in the ER. Furthermore, tumors arising from the antisense ORP150
C6 glioma transfectants demonstrate an initial phase of growth comparable to the
wild-type glioma cells, which was followed by marked regression and decreased
angiogenesis within 8 days [15].
The Unfolded Protein Response
In addition to inadequate vascularization of tissues impinging on oxygen delivery
to cells, this condition can also inhibit the delivery of nutrients like glucose and the
removal of acidic waste products. These changes in the extracellular environment of
cells alter the normal homeostasis of the endoplasmic reticulum (ER), which disrupts
folding and processing of secretory pathway proteins and leads to the accumulation of
unfolded proteins in this organelle [16]. This activates the UPR; a complex signal
transduction pathway that is largely cytoprotective and aims to decrease the detrimental
effects of accumulated unfolded proteins. If normal homeostasis is not restored during
prolonged stress conditions, the UPR can induce apoptosis in these cells in order to
protect the organism [17].
The UPR was first delineated in yeast as a relatively simple signaling pathway
[18]. In higher eukaryotes this cellular stress pathway is mostly conserved but greatly
expanded and far more complex (Figure 1-2). In mammalian cells there are three
transmembrane proteins that sense ER stress through their luminal domains and activate
downstream responses through their cytosolic domains. Ire1 was the first to be identified
based on its homology to the yeast ER kinase that is the single UPR transducer in this
organism [19]. On sensing stress in the ER, Ire1’s kinase activity is activated, which in
turn activates an endonuclease activity in its C-terminus that excises 26 nucleotides from
the X-box binding protein-1 (XBP-1) transcript. After religation, the resulting frameshift
encodes an active transcription factor XBP-1(S) that regulates the expression of several
downstream elements of the UPR [20, 21]. In addition to Ire1 signaling, mammalian
cells also transiently inhibit cap-dependent translation through activation of a PKR-like
ER localized kinase (PERK). Activated PERK phosphorylates eIF2α, which inhibits
loading of the 80s ribosomal complex on mRNAs. The resulting inhibition of protein
translation leads to a loss of cyclin D1 from cells causing a G1 arrest [22], thus
preventing the proliferation of cells experiencing stress. Contrary to the global inhibition
of translation in PERK-activated cells, synthesis of the ATF4 transcription factor is
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Figure 1-2. Components of the mammalian ER stress response. The accumulation
of unfolded proteins in the ER leads to the activation of three ER membrane proteins
Ire1, PERK, and ATF6 that act as signal transducers. These three arms of the response
are largely cytoprotective and serve to regulate downstream targets which are ultimately
responsible for the up-regulation of ER chaperones, inhibition of translation, cell cycle
arrest, and a number of other transcriptional responses.
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increased [23]. ATF4 transactivates expression of genes such as CHOP [24], which is
proapoptotic [25], and GADD34, which is a regulatory subunit of the PP1 phosphatase
that dephosphorylates eIF2α allowing translation to resume [26]. PERK also activates
NFκB expression [27], which positively regulates anti-apoptotic proteins like Bcl-2
during ER stress, thus contributing to the balance between survival and death signals.
ATF6, which is the third arm of the UPR pathway, is a bZIP transcription factor. ATF6α
and β are ER-associated transmembrane proteins with lumenal stress sensing domains
[28]. Upon activation, the ATF6 proteins are transported to the Golgi and cleaved by S1P
and S2P proteases. The cytosolically oriented transcription factor domain is liberated and
regulates the transcription of XBP-1 and other important ER chaperones [29]. These
signal transducers collectively act to protect the cell during stress conditions by
increasing the expression of chaperones that enhance the folding capacity of the ER, by
transiently inhibiting protein translation to decrease the load of unfolded proteins, and by
increasing the degradative capacity of the cell. If stress conditions do not subside, the
UPR activates ER localized caspase-4/12 [30, 31] to eliminate cells experiencing
prolonged stress and ultimately protecting the organism.
Cancer cell metabolism is regulated partly by cues from the tumor
microenvironment
Once tumor cells accumulate mutations in genes that enable them to bypass cell
cycle checkpoints, apoptotic pathways and in some cases alter cancer cell metabolism,
increasing studies show that the heterogeneous tumor microenvironment also contributes
to the metabolic phenotype of cancer cells [32]. Normally non-dividing, differentiated
cells rely primarily on mitochondrial oxidative phosphorylation to generate energy
required for various cellular processes, although under reduced levels of oxygen, or
anaerobic conditions, they can convert glucose to lactate to supply their energy needs
through a process known as glycolysis. However, proliferating cells, including cancer
cells, usually metabolize glucose through aerobic glycolysis to produce energy even
when oxygen levels are sufficient. Glycolysis is an inefficient way to generate energy as
the metabolism of glucose to lactate generates only 2ATPs (adenosine 5’-triphosphate)
per molecule of glucose whereas oxidative phosphorylation generates 36 ATPs from one
molecule of glucose [33]. The reason for tumors and other proliferating cells to switch to
an inefficient method for generating energy that would seem to be contrary to their
requirements has been unclear. However, recent studies propose that this phenomenon
known as the “Warburg effect” results in the production of metabolic byproducts from
glycolysis, such as nucleotides, amino acids and lipids, that may be beneficial to cell
proliferation [33]. Due to the highly proliferative nature of tumor cells, the ability to
metabolize nutrients in a manner conducive to producing new cells rather than efficient
energy production may provide an explanation of why cancer cells shift over to
glycolysis. The shift in cancer cell metabolism is a powerful tool used in the clinic to
image tumors with increased glucose uptake through the use of 18F-deoxyglucose
positron emission tomography (FDG-PET). Increased glucose uptake in tumors correlates
with poor prognosis and higher metabolic rate, which is suggested to contribute to a
malignant phenotype in several tumor types [34].
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Role of HIF pathway in tumor angiogenesis
Angiogenesis is a complex process that requires multiple gene products regulated
by different cell types to converge and stimulate blood vessel formation. Hypoxia plays a
major role in regulating a large number of genes involved in different steps of
angiogenesis including, upregulating expression of various growth factors like VEGF,
fibroblast growth factor and angiopoietins. This stress pathway also has the ability to
induce endothelial cell migration and tube formation in tissue culture. In addition to its
role in regulating molecular determinants of angiogenesis in culture, the HIF pathway
also plays an important role in tumor angiogenesis. Up-regulation of the HIF pathway in
solid tumors is via a combination of limited oxygen supply in the microenvironment and
genetic mechanisms. The HIF pathway can be induced by several growth-promoting
stimuli and oncogenic pathways that are up-regulated in tumors like insulin, insulin-like
growth factor-1, epidermal growth factor and mutant Ras and src kinase pathways.
Mutation in several tumor suppressor genes like pVHL, PTEN, p53 and p14ARF activate
the HIF pathway. Given that the HIF pathway plays a role in regulating multiple steps of
the angiogenic process and this pathway is activated in tumors, it is plausible that the HIF
pathway could be used as a potential anticancer target [35]. However, the effects of
inactivating the HIF pathway in embryonic stem cell derived teratomas have been
variable, with neither vascularity nor growth being correlated with an intact HIF system
in every study conducted [36-38]. Another study engineered an inducible knockdown of
HIF1 in D54-a glioblastoma cell line and observed that inhibition of HIF1 during the
early-stages of tumor development is more efficacious at decreasing tumor burden when
injected in the flank of the animal. Inhibition of HIF1 at the late-stages in tumor
development had no significant effect. The same study used a different tumor model and
showed that HIF1 plays no role in regulating the growth of tumors derived from MDAMB435- cell line. On further investigation, the authors observed that the tumors derived
from MDA cell line were still responsive to hypoxia, however, VEGF secretion in this
line was through a HIF-independent mechanism making them unresponsive to inhibition
of HIF1 [39].
Is the tumor dependence on UPR activation due to it having a role in angiogenesis?
Once tumor cells acquire the necessary mutations to overcome cell cycle
checkpoints and interfere with apoptotic pathways, limitations in their extracellular
environment can pose the next hurdle to uncontrolled cell growth. The rapid division and
high metabolic rate of many tumors increases their demand for essential nutrients and
oxygen, which is further exacerbated as their growth increases the distance of some cells
within the tumor mass from existing vasculature [4] as illustrated in Figure 1-3. Indeed,
unless the tumor is able to rectify this situation, it enters a dormant state [40]. The
presence of hypoxic cells in localized regions of solid tumors is well documented
clinically and experimentally. Perhaps counter intuitively this is correlated with a more
aggressive phenotype and a poorer prognosis [41], which in part stems from the fact that
cytoprotective signal transduction pathways, including the UPR, are activated by these
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Figure 1-3. Tumor angiogenesis is regulated by multiple stress pathways activated
in cancer cells. Rapidly proliferating tumor cells have an increased demand for nutrients,
ATP and oxygen due to a high metabolic rate (green). As the tumor mass grows in size,
cells that are more distant from a functional blood vessel are deprived of nutrients and
oxygen and become hypoxic (blue). Tumor cells adapt to these adverse conditions by
activating stress signaling pathways like the UPR and HIF. The UPR has several
protective functions that assist tumor cell survival, including up-regulation of several
proangiogenic factors such as VEGF by UPR-inducible transcription factors XBP1(S)
and ATF4. Activation of the HIF signaling pathway stabilizes HIF1 and HIF2, which
can transactivate VEGF gene expression during hypoxic/anoxic conditions. The UPR
and HIF signaling pathways are thus both likely to contribute to angiogenesis and tumor
growth.
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conditions. Unlike HIF pathways that are only activated in regions of the tumor that are
further than approximately 0.2 mm from blood vessels [1], the UPR appears to be
activated through out tumor masses due to their high metabolic rates, which might
suggest that different subsets of cells within the tumor may experience different
combinations of these two stress pathways. Our studies will assess the contribution of
these pathways in regulating VEGF expression in cells experiencing both stresses.
To elucidate the role of Ire1 in regulating tumor growth and angiogenesis in vivo,
two separate studies engineered U87 human glioma cells with either an Ire1 dominant
negative mutant or a control empty vector and then orthotopically implanted them in
mice [42, 43]. In both studies, tumors derived from cells expressing the Ire1-dominant
negative mutant were significantly smaller, less vascularized but more highly infiltrative
as compared to their control counterparts. Similar results were obtained using a chick
chorio-allantoic membrane (CAM) assay [43]. Although blocking the expression of Ire1
in tumor cell lines introduced into animals resulted in the inhibition of
neovascularization, somewhat counter-intuitively it also modified the growth
characteristics of the cells and promoted tumor cell invasion. This highly
infiltrative/avascular phenotype has been reported by several other laboratories in
response to various methods of blocking angiogenesis, although the molecular
mechanism for this striking phenotype is still unknown. Supporting data for the role of
Ire1 in tumor growth came from a study where Ire1’s downstream target XBP-1 was
examined using transformed XBP-1 wild-type and null MEFs. In this case, the XBP-1
null cells severely impeded tumor growth. When extreme hypoxic conditions were used
to activate the UPR in the two cell lines, the XBP-1 null cells had a higher rate of
apoptosis and decreased survival, in keeping with their failure to grow in mice. However
the secretion of the proangiogenic factors VEGF and FGF2 under these culture conditions
at shorter times was not significantly different between the two lines, leading the
investigators to conclude that failure to induce angiogenesis was unlikely to be the reason
the XBP-1 null cells failed to form tumors. Instead, they hypothesized that the
Ire1/XBP-1 axis contributed to tumor cell survival via a mechanism that remained to be
elucidated [44]. It should be noted however that the extreme hypoxic conditions used in
these cell culture assays would be expected to also activate the HIF pathway, which is not
expected to be affected by deletion of XBP-1, although this has not been formally tested.
These results suggests the possibility that in tumors, the UPR may play as large or larger
role than the HIF pathway in promoting angiogenesis and survival, due to the fact that
more cells within the tumor may have activated the UPR.
Cells cultured under hypoxic/anoxic conditions also activate the PERK branch of
the UPR, which controls a translational inhibition program that is shared with other stress
signaling pathways that use distinct eIF2 kinases, and is therefore known as the
integrated stress response (ISR). In addition to the transient inhibition of protein
synthesis that is a hallmark of PERK activation, a number of transcription factors are upregulated that are responsible for many of the changes observed in the ISR. One of these
factors is ATF4/ cyclic AMP (cAMP)-responsive element binding protein 2 that regulates
the ISR and protects the cell against metabolic consequences of ER stress [45]. To
determine if the PERK pathway might also contribute to tumor survival, K-ras
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transformed PERK wild-type and null MEFs were injected into the flank of athymic
Nu/Nu mice. These studies show that tumors derived from K-ras-transformed PERK null
MEFs are smaller and exhibit less angiogenesis than tumors from cells that express
PERK. These studies also revealed that PERK activation favors endothelial cell survival
and functional blood vessel formation in a tumor microenvironment by preferentially upregulating expression of proangiogenic factors like VCIP, an adhesion molecule that
facilitates integrin binding, cellular adhesion and capillary morphogenesis [46].
UPR activation regulates other proangiogenic factors
Although VEGF is the most potent proangiogenic factor, there are other factors
including FGF2, IL8, IL6, VCIP, and angiogenin that play a role in promoting
angiogenesis [47]. Microarray analysis of polysome-bound RNA demonstrated that a
subset of proangiogenic transcripts including VCIP, an adhesion molecule that promotes
capillary morphogenesis, is preferentially translated in a PERK-dependent manner [46].
In a mouse model of pancreatic islet carcinoma, increased expression of several
Fibroblast Growth Factor (FGF) family members including FGF2 is observed when the
binding of VEGF to its receptor-VEGFR2 is inhibited by a monoclonal anti-VEGFR2
antibody [48]. Anti-VEGFR2 is currently used to inhibit angiogenesis in the treatment of
some cancers. A clearer understanding of the compensation mechanisms that exist
between proangiogenic factors is important for the development of therapeutic agents.
IL8, FGF2 and angiogenin are induced by different stress conditions including, hypoxia
and low glucose [49]. It has been reported that hypoxia can induce IL8 expression in a
HIF-1 deficient colon cancer cell line. This induction was mediated by enhanced
production of ROS and activation of NFB [50]. Since NFB can be activated
downstream of PERK [27], it is conceivable that UPR activation can induce IL8
expression via this transcription factor.
In summary, when I began my dissertation studies, there were preliminary data
from a microarray study conducted in our lab to suggest that UPR activation can promote
the expression of a significant number of proangiogenic factors in cultured cells [49]. I
wanted to understand how many of these factors are UPR targets. We then focused on
understanding the regulation of the most potent and best characterized proangiogenic
factor- VEGF by the UPR. It was important to determine which UPR-inducible
transcription factor played a critical role in regulating its expression. The fact that tumors
activate both HIF and UPR pathways raises the questions of which pathway is most
critical in promoting angiogenesis (Figure 1-4), whether different cells within the tumor
mass rely on distinct pathways, and what affect will dismantling the UPR have on VEGF
production in a tumor model. These studies will determine if the UPR might represent a
druggable pathway for inhibiting angiogenesis and treating cancer.
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Figure 1-4. Regulation of angiogenic factors by stress-activated pathways.
Angiogenesis is regulated by a fine balance between proangiogenic factors (red circles)
and antiangiogenic factors (blue circles) under normoxic conditions. The UPR is a
positive regulator of angiogenesis, since its activation increases expression of
proangiogenic factors and inhibits anti-angiogenic factors. The HIF signaling pathway
also increases expression of proangiogenic factors under hypoxic conditions. Since
certain regions of the tumor mass encounter environmental conditions that lead to the
activation of both pathways, UPR and HIF, it is conceivable that they could either
synergize or compete to increase expression of proangiogenic factors.
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Specific Aims
Aim 1: To determine the role of the UPR in regulating the expression of
proangiogenic factors and identify the mechanism(s) and critical signaling components of
the response that do so. Preliminary microarray analysis on Daoy, a human
medulloblastoma cell line, treated with thapsigargin, an UPR stress inducer, showed that
in addition to increased expression of known UPR target genes there was an upregulation of several proangiogenic factors including, VEGFA, IL-8, FGF2 and
angiogenin. Studies outlined in this aim will:
a) Determine the extent proangiogenic factors affected by ER stress.
b) Confirm these findings by real-time PCR and extend them to other UPR inducers
and other types of cell lines.
c) Determine the mechanism(s) by which VEGF, the best-characterized and most
important proangiogenic factor, is regulated by the UPR.
d) Identify the UPR-induced transcription factors that contribute to VEGF
expression.
Aim 2: To determine the relative importance of the UPR versus HIF signaling in
regulating VEGF expression in cultured human cells. Solid tumors activate multiple
signaling pathways simultaneously including the UPR and HIF
In order to determine the contribution of these two pathways to VEGF expression, we
will:
a) Establish the fold induction of VEGF with the two stresses alone and in
combination.
b) Identify the UPR-induced transcription factor(s) that regulate VEGF in response
to ER stress.
c) Determine the effects on pathway-specific transcription factors in binding to the
VEGF promoter when both stresses are present.
d) Assess to what extent each pathway contributes to VEGF expression under
conditions of hypoxia and ER stress.
Aim 3: To determine the importance of the UPR in regulating tumor
angiogenesis in vivo. Once we have identified the critical UPR-inducible transcription
factor(s) that regulate expression of VEGFA in cultured cells, we wish to determine the
relative effect of the UPR in contributing to angiogenesis in a xenograft model. To do so,
we will:
a) Engineer human cell lines in which the critical UPR-regulated transcription
factor(s) can be conditionally knockdown.
b) Determine the effects of inhibiting expression of the transcription factor on tumor
cell line growth in culture and in animals.
c) Perform xenograft studies to assess its contribution in mediating angiogenesis in
an animal model.
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CHAPTER 2.

THE UNFOLDED PROTEIN RESPONSE POSITIVELY
REGULATES PROANGIOGENIC FACTORS2
Introduction

Changes in the extracellular environment of a cell can adversely affect the normal
homeostasis of the endoplasmic reticulum (ER), which disrupts the folding and
processing of secretory pathway proteins. The resulting accumulation of unfolded
proteins in the ER increases the demands for molecular chaperones and folding enzymes
and activates a signal transduction cascade known as the unfolded protein response
(UPR) [51]. This multi-component signal transduction pathway is largely cytoprotective;
serving to decrease the detrimental effects of accumulated unfolded proteins by
increasing molecular chaperones that bind to them, decreasing protein synthesis to limit
the accumulation, and finally increasing the degradative capacity of the cell to eliminate
them. However if normal homeostasis is not restored during prolonged stress conditions,
the UPR can induce apoptosis in these cells in order to protect the organism [51, 52]. In
mammalian cells, the UPR is controlled by three resident ER transmembrane proteins
that “sense” ER stress and activate signals to downstream elements; Ire-1, PERK and
ATF6. Ire-1 is an ER localized transmembrane protein, which has a kinase and
endoribonuclease domain in its cytosolic tail. On sensing ER stress, Ire-1 is
phosphorylated in trans, which in turn activates its endonuclease domain leading to the
excision of 26 bases from the X-box binding protein (XBP-1) transcript [53]. The
resulting frame shift encodes a fully active transcription factor XBP-1(S), which
up-regulates expression of a number of resident ER proteins that contribute to folding or
degradation of unfolded or misfolded proteins [21, 54]. In addition to Ire-1 signaling,
mammalian cells also transiently inhibit cap-dependent protein translation and arrest cells
in the G1 phase of the cell cycle through activation of the PKR-like ER kinase (PERK)
[23, 55]. Contrary to this global inhibition in protein translation occurring in PERKactivated cells, synthesis of the ATF4 transcription factor is increased during ER stress
[23]. ATF4 transactivates expression of a number of genes including CHOP [56], a
pro-apoptotic protein, and GADD34 [26], which reverses the block in translation. PERK
also activates NFκB [27], a pro-survival protein, thus contributing to the balance between
survival and death signals. Lastly, activation of ATF6 results in its translocation to the
Golgi and cleavage by the S1P and S2P proteases to release the cytosolically oriented
active transcription factor that up-regulates expression of XBP-1, as well as folding
enzymes and ER chaperones, such as PDI and BiP [57, 58].
In addition to protecting cells during physiological and chemical conditions that
adversely affect protein folding in the ER, there is increasing evidence to show that the
UPR also plays an important role in normal development and physiology. This includes
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liver development [59], plasma cell differentiation [60, 61], bone development [62, 63],
and normal pancreatic homeostasis [64]. Mice that are null for either XBP-1 [59] or its
upstream activator Ire1α [65-68] die at day E12.5 due to hepatoinsufficiency. In both
cases, this was later confirmed to be due to an inability to produce XBP-1(S), a major
regulator of hepatic development. In addition to liver, pancreas, and muscle, XBP-1(S) is
also highly expressed in the placenta [65], and Ire1α null embryos show evidence of
placental abnormalities. To determine the role of Ire1 in this tissue, a recent study
generated mice lacking Ire1α by crossing Ire1α+/- mice with Mox2+/Cre transgenic mice
[65]. Mox2 is ubiquitously expressed except in the labyrinthine trophoblasts of the
placenta. This allowed Ire1-deficient embryos to be produced that have normal levels of
Ire1 in the placenta [65]. This study revealed that loss of Ire1α in the placenta led to
decreased vascular endothelial growth factor (VEGFA) production, which is a major
inducer of angiogenesis, thereby resulting in severe dysfunction of this highly
vascularized tissue.
Angiogenesis refers to the sprouting, migration and remodeling of existing blood
vessels [69] and plays an important role in a number of normal physiological processes
including embryonic development, wound healing, and the female reproductive cycle. It
also plays a role in several pathological conditions including ischemia and cancer.
Angiogenesis is regulated by a fine balance between factors that stimulate the formation
of new blood vessels and those that inhibit it [70, 71]. Proangiogenic factors such as
VEGF, fibroblast growth factors (FGFs), platelet derived growth factors (PDGFs), and
IL8 are released by cancer cells experiencing decreased oxygen and nutrient supplies [7274]. These factors act as ligands that bind to specific receptors on endothelial cells,
causing them to proliferate and to release matrix metalloproteinases that degrade the
extracellular matrix, allowing them to migrate toward the angiogenic stimulus in order to
establish new blood vessels [72]. The predominant and best studied proangiogenic factor
is VEGFA, a homodimeric heparin binding glycoprotein that is produced in several
isoforms due to alternative splicing. The different isoforms of VEGFA (206, 189, 165,
145 and 121) have varying expression patterns and contrasting properties [75]. Of these
VEGF165 is the predominant and best characterized isoform, and plays an important role
in mediating angiogenesis [76]. All VEGF isoforms are synthesized and processed in the
endoplasmic reticulum (ER) and transported through the secretory pathway [72, 77].
The HIF (hypoxia inducible factor) pathway is the best characterized cellular
stress pathway that leads to the up-regulation of proangiogenic factors in response to
inadequate oxygen delivery [78]. HIF-1 and HIF-2 are heterodimeric transcription
factors consisting of an oxygen-labile α subunit and a constitutively expressed β subunit.
Hypoxia stabilizes the α subunit, thereby activating the HIF complex, which in turn binds
to the promoters of target genes such as VEGF and other proangiogenic factors and
transactivates them [79]. Prolonged hypoxia can also increase VEGFA mRNA stability
leading to further increases in VEGFA production [80]. In addition to the role of the HIF
signaling pathway in up-regulating VEGF expression, several recent studies demonstrate
that the UPR also contributes to VEGF transcription [81] and protein processing in the
ER [15]. Using microarray analysis, we found that in addition to VEGFA a large number
of proangiogenic factors were up-regulated by UPR inducers. The up-regulation of
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several of these factors by ER stress was as robust as, or even greater than, that achieved
with hypoxia. We found that two UPR-regulated transcription factors bound directly to
the VEGFA promoter in response to ER stress and contributed to its transcription. In
addition, activation of AMP kinase stabilized the VEGFA transcripts, further contributing
to VEGFA mRNA levels. Our finding that a number of regulators of angiogenesis are
targets of the UPR argues that this physiological process should be added to the growing
list of normal homeostatic and developmental processes that this stress pathway controls.
Results
UPR activation results in the transcriptional up-regulation of a number of
proangiogenic factors
We wished to characterize the UPR in a solid tumor cell line that could ultimately
be used in xenograft studies to ensure that this stress response was fully active and that all
branches were intact. To do so, we treated Daoy, a human medulloblastoma cell line
with thapsigargin, a Ca2+ ATPase inhibitor and potent inducer of the UPR, and performed
genome-wide microarray analyses. Overall, we identified 1069 probe sets with
differential expression after either 3 or 8 hours of thapsigargin treatment compared to
untreated cells. Further analysis of this data confirmed significant enrichment of the
expected UPR target genes, including ER chaperones, folding enzymes, and proteins
involved in ER associated degradation (ERAD), as well as the transcription factors that
are known to up-regulate them in response to ER stress. In addition to UPR targets,
somewhat unexpectedly, gene ontology analysis revealed a significant enrichment of
genes associated with the regulation of angiogenesis. A total of 185 genes on the array
are annotated as being associated with angiogenesis. As many of these encode
endothelial cell-specific proteins or cell surface receptors on endothelial cells, we limited
our further analysis to the 33 genes that are secreted proteins or transcription factors that
either positively or negatively regulate angiogenesis. Of the 19 genes that are
characterized as positive regulators of angiogenesis, 13 showed a greater than 2-fold
increase in expression in at least one time point after thapsigargin-treatment (Table 2-1).
Additionally expression of one negative regulator of angiogenesis, vasohibin (VASH1)
was decreased with ER stress. These data suggest that regulating angiogenesis is likely
to be a major function of the UPR.
Comparison of UPR inducers with hypoxia in the up-regulation of proangiogenic
factors
To confirm the induction of proangiogenic factors by the UPR, we treated cell
lines with UPR inducers and compared the magnitude of their induction to that achieved
with conditions that activate the HIF pathway using quantitative Real-Time PCR
(qRT-PCR) (Figure 2-1). We confirmed by western blot analyses that CoCl2 and the
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Table 2-1. UPR activation enhances expression of proangiogenic factors.
Gene Symbol
ANG
ANGPT2
CTGF
EPAS1
EREG
FGF2
F3
IL1A
IL6
IL8
KLF5
TGFB2
VEGFA
VASH1

Gene Name
Angiogenin
Angiopoietin-2
Connective tissue growth factor
Endothelial Pas domain protein 1
Proepiregulin
Fibroblast growth factor-2
Thromboplastin
Interleukin-1 α
Interleukin-6
Interleukin-8
Kruppel-like factor 5
Transforming growth factor beta-2
Vascular endothelial growth factor A
Vasohibin
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Angiogenic
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Negative

Fold Change
3 Hour
8 Hour
2.4
8.1
-2.6
2.2
2.2
1.4
1.8
2.6
2.3
6.3
1.5
3.1
2.9
1.6
4.4
10.8
4.8
7
54.25
27.9
2.6
3.5
4.1
2.9
1.7
2.7
-1.3
-3

Figure 2-1. Up-regulation of proangiogenic factor mRNA by the UPR and
hypoxia. Daoy, NB1691, SKNAS, C6 and NIH3T3 cells were treated with 100 µM
CoCl2, 1% O2 hypoxia (Hy), 2.5 µg/ml tunicamycin (Tm), 1 µM thapsigargin (Tg), or no
glucose media (No Glu) for 24 hours. RNA was extracted for qRT-PCR analysis and
mRNA fold induction relative to the untreated control sample, which was set to 1, was
determined for (A) VEGF (white bars) (B) angiogenin (striped bars) (C) FGF2
(chequered bars) and (D) IL8 (grey bars). Experiments were performed in triplicate
(values are mean ± SD).
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level of hypoxia (1% O2) used in our experiments induced HIF1α and BNIP3, its
downstream target, but did not induce UPR targets. Importantly, the UPR inducing agents
did not activate the HIF signaling pathway (Figure A-1). Thus the conditions we used in
our analysis allowed us to specifically activate these two stress pathways independently.
Five different cell lines were treated with a variety of UPR inducers (e.g., tunicamycin,
thapsigargin, and no glucose) and with two different inducers of the HIF pathway (e.g.,
CoCl2 and 1% oxygen) for 24 hours, and the induction of four of the best characterized
proangiogenic factors: VEGFA, bFGF, angiogenin and IL8 was measured. We also
confirmed that downstream UPR target genes like CHOP and BiP mRNA were upregulated by ER stress in each of the cell lines tested (Figure A-2). As expected, all four
factors were up-regulated by hypoxic conditions, although the magnitude varied
dramatically between cell lines, largely due to differences in their basal levels of
synthesis (Figure A-3). When UPR inducers were used, we found that in many cases the
induction of the four proangiogenic factors was nearly as high as or even higher than that
achieved with hypoxia, although there were some interesting differences. Hypoxia was a
strong inducer of VEGFA mRNA in the NB1691 neuroblastoma cell line, while ER stress
had little effect on VEGFA levels. Conversely ER stress induced VEGFA in the NIH3T3
fibroblast line, but hypoxia did not (Figure 2-1A). Similarly ER stress induced FGF2
expression greater than hypoxia in the Daoy line, whereas neither stress condition
stimulated its production in the C6 and NIH3T3 cell lines, perhaps due to the high levels
of basal expression of FGF2 in these two lines (Figure 2-1C). In keeping with the
microarray data, angiogenin was modestly induced in the Daoy cell line and the NB1691
line, but in the other three lines there was very little effect with either hypoxia or ER
stress inducers (Figure 2-1B), again in keeping with higher basal levels in these lines.
Finally, increases in human-specific IL8 expression were much more dramatic with ER
stress than with hypoxia in all three human cell lines (Figure 2-1D).
UPR activation increases VEGFA mRNA stability via AMPK
In this study we focused on determining the mechanism by which the UPR
regulates VEGFA expression, as VEGFA is the best characterized stimulator of
angiogenesis and represents a therapeutic target for treating cancer as well as several
ischemic, infectious and inflammatory disorders [82]. Additionally, we favored this
target because in most of the lines we examined, including mouse cells, VEGFA was
induced to higher levels with ER stress than with hypoxia. We chose the C6 cell line for
these experiments, because it had a low basal expression of VEGF which was potently
induced by ER stress, previous studies used this line to study VEGF gene regulation by
hypoxia, and this line was used in xenograft studies to determine the role of
ORP150/GRP170 in VEGF processing and and secretion. VEGFA mRNA levels increase
in response to hypoxic conditions via a combination of an enhanced transcription at early
time points coupled with an increase in the stability of the mRNA at later times [83]. To
investigate whether UPR activation might also increase VEGFA mRNA stability, we
examined the turnover of VEGFA mRNA under control and various stress conditions
(Figure 2-2A). Cells were pretreated with hypoxia or two different UPR
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Figure 2-2. UPR activation stabilizes VEGF mRNA via AMPK. (A) C6 cells were
pre-treated with normal culture conditions (NT-circle), 1% O2 (Hy-square), thapsigargin
(Tg-triangle), or no glucose media (No Glu-cross) for 6 hours. Actinomycin D (5 µg/ml)
was added to the various cultures to block further transcription. At the indicated times,
total RNA was extracted and subjected to qRT-PCR to determine VEGF mRNA levels.
The mean values of data from duplicate experiments are presented (± SD). (B) C6 cells
were either left untreated or treated as indicated in the figure in the presence or absence
of Compound C for 9 hours or 14 hours. Western blot analysis was performed on cell
lysates to determine levels of p-AMPK. Hsc70 was used as loading control. (C-D) C6
cells were pretreated with different stress inducers for 6 hours as indicated. No inhibitor
(black) or compound C (AMPK inhibitor- white) was added to the cells as indicated for
an additional 8 hours. Total RNA was extracted for qRT-PCR to determine VEGF mRNA
(C) and VEGF hnRNA (D) levels. Experiments were performed in triplicate (values are
mean ±SD).
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inducers and then incubated with actinomycin D to inhibit further transcription. In
control cells the low level of basal transcripts were rapidly degraded in keeping with
previous studies [80, 84]. For all three stress inducers, there was a reproducible increase
in VEGFA mRNA at 30 minutes after adding actinomycin D, which is compatible with an
increase in transcription occurring before the inhibitor takes effect. We found that
although hypoxic conditions led to an initial increase in VEGFA levels, the mRNA was
rapidly degraded. This is consistent with a previous report using C6 cells, which showed
that hypoxia had no significant effect on the half-life of VEGFA mRNA until much later
time points [83]. When cells were pretreated with the two UPR inducers, we found that
after the initial burst in VEGFA transcripts they decayed significantly slower than in
control or hypoxia-treated cells. (Figure 2-2A), arguing that ER stress leads to increased
VEGFA mRNA stability at relatively early times in the response.
The increase in VEGFA mRNA stability observed after prolonged exposure to
hypoxic conditions is due to the binding of a hypoxia-inducible protein complex, such as
HuR, to the ARE (adenylate-uridylate rich elements) region in the 3’UTR region of
VEGFA mRNA [80]. Additionally, stress activated protein kinases such as AMPK,
p38MAPK, JNK, and PI3K have been implicated in increasing VEGFA mRNA stability
through their action on the AU rich region of the 3’UTR [85-88]. We used a variety of
kinase inhibitors to determine if any of their targets might play a role in increasing the
stability of VEGFA mRNA during ER stress. When the UPR-activated cells were
incubated with compound C, an AMP kinase inhibitor, there was a significant reduction
in VEGFA transcripts (Figure 2-2C), suggesting that this kinase played a role in the UPRinduced stabilization of VEGFA. Activation of AMPK by ER stress was confirmed by
western blotting, as was the efficacy of its inhibitor, Compound C (Figure 2-2B). We
also co-incubated UPR activated cells with inhibitors of the PI3 and JUN kinases, but
found that they had no affect on VEGFA mRNA levels in response to UPR activation
(data not shown). As an additional control, the effect of the AMPK inhibitor on VEGFA
mRNA levels was examined in cells pre-treated with hypoxia for 6h (Figure 2-2C), which
was previously shown to be not long enough to stabilize VEGFA transcripts [83].
Unexpectedly, we found that VEGFA stability was actually increased in hypoxia
treated cells that we incubated with Compound C, although we do not understand the
basis for this effect. To verify that the effects of this inhibitor was specifically on
VEGFA mRNA stability and did not alter transcription of the VEGFA gene, we treated
cells with the various combinations of kinase inhibitor and stress inducers and examined
heteronuclear VEGFA RNA (hnRNA) levels (Figure 2-2D), which can be used as a
measure of transcription. We found that there was no indication that this inhibitor
affected VEGFA transcription, thus confirming that VEGFA transcripts are stabilized
during ER stress, which apparently is due to the activation of the AMP kinase.
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UPR activation increases the transcription of VEGFA
Our analysis of VEGFA hnRNA in the experiment described above revealed that
the unprocessed hnRNA levels were higher in cells treated with thapsigargin or no
glucose than in control cells. This suggested that VEGFA might also be transcriptionally
regulated in response to ER stress. Prior to using hnRNA levels as a measure of the
transcription rate, we first confirmed that the splicing of VEGFA mRNA was not
significantly affected by UPR activation. Cells were pretreated for 6 hours with the
indicated stressors, and actinomycin D was added to inhibit further transcription.
Heteronuclear RNA was then measured at the indicated time points. We found that
VEGFA hnRNA decreased at a fairly similar rate in control and stress activated cells
through at least eight hour of treatment, arguing that these stresses did not dramatically
affect splicing up to this point (Figure 2-3A). Therefore, the measurement of VEGFA
hnRNA could be used as an indication of the transcription rate of this gene in response to
UPR activation (Figure 2-3B). Cells incubated in media containing no glucose, increased
VEGFA transcription to a much greater extent than either thapsigargin or hypoxia at all
time points measured, which is in keeping with the 30 minute time point in Figure 2-2A.
Thapsigargin was as good as or better than hypoxia at inducing VEGFA transcription
throughout the course of the experiment. Thus, the increased transcription rate, coupled
with the stabilization of VEGFA transcripts, accounts for the higher steady state level of
VEGFA mRNA in response to thapsigargin compared to hypoxia in this cell line (Figure
2-2A). Although the transcription rate of VEGFA appeared to be the highest in the
presence of no glucose, this is not reflected in the steady state levels after 24 hours of
treatment (Figure 2-2A), which may be due to some inhibition of splicing occurring at
later time points.
XBP-1 binds to two regions in the rat VEGFA promoter
To identify potential binding sites for various UPR-inducible transcription factors,
we analyzed the human, mouse and rat VEGFA promoters using the computer programs
rVista and TRANSFAC (Figure A-4). In addition to HIF sites, the promoters of all three
species have a number of potential binding sites for the UPR-induced transcription
factors XBP-1 and ATF4, whereas only the mouse promoter has a single ATF6 site. We
first assessed whether XBP-1(S) bound to any of the five potential sites in the rat
promoter in response to ER stress using a chromatin immunoprecipitation (ChIP) assay,
since the C6 rat glioma was used for both the mRNA stability and transcription assays.
Indeed, XBP-1(S) could be detected at two different sites (i.e., one at ~1.9kb and one at
~5.2kb up-stream of the transcription start site) in response to both thapsigargin and no
glucose treatment (Figure 2-4B). We were unable to detect XBP-1(S) binding to the
remaining three potential sites in these cells upon UPR activation, suggesting that either
they are not used or that the anti-XBP-1(S) antiserum used to immunoprecipitate the
chromatin could not gain access to these sites. As a positive control, we showed that
XBP-1 binds to the ERdj3 promoter (Figure 2-4C), as documented previously [89]. We
detected XBP-1(S) protein in ER stressed but not in untreated C6 cell lysates that were
used for the chromatin immunoprecipitation assays (Figure 2-4D).
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Figure 2-3. UPR activation increases VEGF transcription rate. (A) C6 cells were
pre-treated with normal culture conditions (NT-circle), 1% O2 (Hy-square), thapsigargin
(Tg-triangle), or no glucose media (No Glu-cross) for 6 hours as indicated. Actinomycin
D (5 µg/ml) was added to block further transcription. At the indicated times, total RNA
was extracted and subjected to qRT-PCR to determine the kinetics of the disappearance
of VEGF hnRNA in control and stressed cells. (B) C6 cells were untreated (NT-black),
treated with 1% O2 (Hy-grey), thapsigargin (Tg-striped) or no glucose media (No Gluwhite) for the indicated times. Total RNA was extracted, and VEGF hnRNA was
quantitated by qRT-PCR. Experiments were performed in triplicate (values are mean
±SD).
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Figure 2-4. XBP-1 binds to two regions in the rat VEGF promoter in
response to ER stress and contributes to increasing VEGF transcription rate. (A)
Potential XBP-1 sites in the rat VEGF promoter. (B) Cross-linked chromatin from C6
cells that were untreated (NT), thapsigargin-treated (Tg), or incubated in no glucose
media (No Glu) for 8hours were immunoprecipitated with anti-XBP-1 or with a control
antiserum (anti-BiP). Ten-fold serial dilutions of precipitated chromatin and input
controls were used for PCR amplification. (C) As a positive control, primers spanning the
XBP-1 binding region on the ERdj3 promoter were used to PCR amplify the anti-XBP-1
precipitated chromatin (D) XBP-1(S) protein levels were detected in C6 cells treated with
Tg and No Glu media using Western blot analysis. (E) XBP-1 wild-type (black) or null
(white) MEFs were untreated (NT), thapsigargin-treated (1µM), treated with media
lacking glucose (No Glu) or homocysteine-treated (10 mM) for 14 hours. Cell lysates
were prepared and XBP-1(S) was detected by western blot analysis. (F-G) Cells were
treated as in (E) and total RNA from the indicated samples was subjected to qRT-PCR to
quantify VEGF hnRNA (F) or VEGF mRNA (G) at the indicated time points. RNA
levels were expressed relative to the control untreated samples for each line, which was
set to 1. Experiments were performed in triplicate (values are mean ± SD).
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XBP-1 mediates increased expression of VEGFA following ER stress
To determine the contribution of XBP-1 to the up-regulation of VEGFA
transcription, we made use of XBP-1 wild-type (XBP-1 wt) and null (XBP-1 ko) mouse
embryonic fibroblasts (MEFs). Examination of these cells by western blotting confirmed
that no XBP-1(S) protein could be detected in the XBP-1 null cells in response to UPR
induction (Figure 2-4E). Next we compared the fold induction of both VEGFA hnRNA
(Figure 2-4F) and VEGFA mRNA (Figure 2-4G) in both cell lines after treating with
three different ER stress inducers; thapsigargin, no glucose media, and homocysteine.
Our qRT-PCR analysis in the XBP-1 wild-type MEFs demonstrated an ~10 fold increase
in VEGFA transcription rate after 8h of either thapsigargin or homocysteine treatment
(Figure 2-4F); whereas no glucose media was a relatively poor inducer of VEGFA
transcription in this cell line, perhaps in keeping with the reduced amount of XBP-1(S)
produced by this stress condition (Figure 2-4E). The transcription rate was highest at 8h
for both thapsigargin and homocysteine treatment, demonstrating that its induction is not
sustained during UPR activation in the wild-type MEFs as was observed in the C6 cell
line. This is mirrored in the total mRNA transcripts, which were also higher at 8 hrs of
stress induction (Figure 2-4G). When the XBP-1 null cells were similarly examined, we
found that there was little or no increase in VEGFA transcription with any of the
treatments, suggesting that XBP-1 played a major role in the up-regulation of VEGFA in
response to ER stress. However, closer analysis of the VEGFA hnRNA data from the two
cell lines revealed that the untreated XBP-1 wild-type MEFs had a lower basal level of
VEGFA hnRNA than the null cells, (Figure A-5). Hence, the exact contribution of
XBP-1 in up-regulating VEGFA was somewhat complicated by the differences in basal
transcription rates between the two lines.
ATF4 contributes to up-regulation of VEGFA expression following UPR activation
Inspection of the human, mouse and rat VEGFA promoters also revealed several
potential ATF4 binding sites (Figures 2-5A and A-4). To determine if any of these sites
was occupied by ATF4 in response to ER stress, we performed ChIP assays in ATF4
wild-type (ATF4 wt) and null (ATF4 ko) MEFs. We were unable to detect binding of
ATF4 to any of the seven potential sites upstream of the transcription start site in
response to thapsigargin treatment (data not shown). However, we did detect
stress-inducible binding of ATF4 to a site at position +900 relative to the transcription
start site in the wild-type ATF4 MEFs but not in the ATF4 null MEFs (Figure 2-5B).
Similar to the wild-type MEFs, we were unable to detect ATF4 binding to any of the five
upstream regions in the rat promoter (Figure A-6). However, unlike the human and
mouse promoter, there does not appear to be a site downstream of the transcription start
site in the rat promoter that corresponds to the one used in murine cells. To determine the
contribution of ATF4 to VEGFA transcription in response to UPR stress inducers, we
analyzed steady state VEGFA hnRNA (Figure 2-5C) and mRNA (Figure 2-5D) levels in
ATF4 wild-type and null MEFs. Although the fold increase in total VEGFA mRNA in
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Figure 2-5. ATF4 contributes to VEGF expression and binds to the mouse
promoter in a stress inducible manner. (A) Potential ATF4 sites in the mouse VEGF
promoter (B) Cross-linked chromatin from ATF4 wild-type or null MEFs that were
untreated (NT) or thapsigargin-treated (Tg) for 6h was immunoprecipitated with antiATF4 or with a control antiserum (anti-BiP). Precipitated chromatin and input controls
were used for PCR amplification. (C-D) ATF4 wild-type (black) or null (white) were
cultured in normal media (NT), thapsigargin-treated (1µM), or tunicamycin-treated
(2.5µg/ml) for 3 and 6 hours. Total RNA from the indicated samples was subjected to
qRT-PCR, and VEGF hnRNA (C) or VEGF mRNA (D) levels were determined and
represented as described above. Experiments were performed in triplicate (values are
mean ± SD).
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response to ER stress was not very dramatic in either the wild-type or null cells, it was
consistently slightly higher in the ATF4 wt MEFs.
ATF6 does not significantly contribute directly to VEGFA expression
Although there were no obvious potential ATF6 binding sites in the human or rat
VEGFA promoters, there was one potential ATF6 binding site in the mouse VEGFA gene
at +1.4kb relative to the transcription start site. Thus, we also examined the potential
contribution of ATF6 in regulating VEGFA transcription. qRT-PCR analysis of VEGFA
mRNA in ATF6 wild-type (ATF6 wt) and null (ATF6 ko) MEFs revealed that ATF6
does not appear to play a significant role in up-regulating VEGFA expression in response
to either tunicamycin treatment or incubation in media lacking glucose (Figure 2-6A).
However, in response to thapsigargin treatment there was a modest, albeit significant,
increase in total VEGFA mRNA in ATF6 wild-type cells compared to null cells. The
difference between the stresses in inducing VEGFA transcripts was a bit puzzling.
Because XBP-1 transcription is regulated by ATF6 and our analysis revealed that XBP1(S) binds to the VEGFA promoter, we examined XBP-1(S) levels in the two lines in
response to the various UPR inducers. Western blot analysis revealed a more dramatic
increase in XBP-1(S) protein levels in the thapsigargin-treated ATF6 wild-type cells
compared to the null cells (Figure 2-6B), whereas there was no obvious difference
between the two tunicamycin-treated cell lines. Somewhat surprisingly, media lacking
glucose did not induce XBP-1(S) in either cell line. These data imply that the higher
levels of VEGFA mRNA observed in the thapsigargin-treated wild-type cells compared to
the null cells might be partly due to a more robust increase in XBP-1(S) levels in the
wild-type cells.
UPR activation increases VEGFA protein levels
Lastly, we measured the effects of the UPR and hypoxia signaling pathways on
VEGFA protein levels in the cells (Figure 2-7A) and in the culture supernatant (Figure
2-7B). We could readily detect VEGFA in lysates obtained from cells treated with all
three of the UPR inducers but not in cells cultured in the hypoxia chamber or treated with
CoCl2 (Figure 2-7A), in spite of the fact that hypoxia increased VEGFA mRNA in this
cell line to about the same level as tunicamycin treatment. A faster migrating
unglycosylated VEGFA was detected in cells treated with tunicamycin and no glucose
media, as these stressors are known to inhibit protein glycosylation. In spite of our
inability to detect VEGFA in hypoxia treated cells, when media from cells treated with
the various UPR inducers and hypoxia were examined, we readily detected an increase in
VEGFA secretion with all stressors (Figure 2-7B). However, the combination of cellassociated and secreted VEGFA with each of the treatments is not consistent with the
mRNA levels. For example, although VEGFA mRNA levels were highest in cells treated
with thapsigargin compared to any of the other four stress conditions (Figure 2-1A), it
was not secreted as well from these cells as from tunicamycin or no glucose treated cells.
Additionally, although both hypoxia and tunicamycin treatment resulted in similar
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Figure 2-6. ATF6 does not significantly contribute to VEGF expression. (A) ATF6
wild-type (black) or null (white) MEFs were untreated (NT), thapsigargin treated (1 µM),
tunicamycin-treated (2.5 µg/ml) or treated with media lacking glucose (No Glu) for 6
hours. Total RNA from the indicated samples was subjected to qRT-PCR, and the VEGF
mRNA levels were determined. (B) XBP-1(S) was detected using western blot analysis
on cell lysates from ATF6 wild-type and null MEFs that were untreated or treated as
indicated. Experiments were performed in triplicate (values are mean ± SD).
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Figure 2-7. UPR activation increases VEGF protein levels and secretion. (A) C6
cells were left untreated or treated as indicated for 24 hours. Western blot analyses on cell
lysates were performed to detect VEGF protein levels. Hsc70 was used as a loading
control. (B) Conditioned media from untreated and treated cells was analyzed for VEGF
secretion by ELISA. (C) Total RNA from the indicated samples was subjected to qRTPCR, and GRP170 mRNA levels were determined and expressed relative to the control
cells.
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increases in VEGFA transcripts, tunicamycin treatment resulted in the secretion of
greater quantities of VEGFA (Figure 2-7B). Previous studies demonstrated that the ER
stress-inducible chaperone GRP170/ORP150 plays an important role in VEGFA
processing and secretion in the C6 cells [15]. Thus we examined the effects of the
various stressors on GRP170 induction at both the mRNA and protein levels. We found
that tunicamycin and no-glucose were potent inducers of GRP170 mRNA (Figure 2-7C)
and protein (Figure 2-7A), whereas thapsigargin only modestly induced this chaperone
and hypoxia had almost no effect on GRP170 levels. Thus the relatively high levels of
VEGFA secretion in tunicamycin and no-glucose treated cells are consistent with the
increased GRP170 levels in these cells.
Discussion
Angiogenesis is a normal physiological process that is important for embryonic
development as well as wound healing [71, 82]. It is carefully controlled by a large
number of secreted factors that bind to receptors on endothelial cells, as well as negative
regulators that inhibit angiogenesis through direct effects on endothelial cells or indirect
effects on growth factor mobilization and activation [70, 82]. Recent studies have shown
that VEGFA, one of the major proangiogenic factors, is a target of the UPR. Our
microarray analysis of UPR targets in thapsigargin-treated Daoy cells confirmed VEGFA
induction, but unexpectedly revealed that there was a significant up-regulation of 12
additional positive regulators of angiogenesis, including secreted proangiogenic factors,
cytokines, and transcription factors that positively regulate proangiogenic factors, as well
as a decrease in one negative regulator of angiogenesis. This argues that the regulation of
angiogenesis is likely to be an important function of the UPR. Of note, the UPR was a
potent inducer of IL8 expression in multiple cells lines (Figure 2-2D). A recent report
demonstrated that addition of IL8 to endothelial cells can induce VEGFA mRNA and
protein levels in a HIF1α-independent manner that requires NFκB activation [90].
Because ER stress also leads to NFκB activation, it is conceivable that IL8 contributes to
VEGF induction during UPR activation in some of our lines. However, although the
NB1691 cell line potently up-regulates IL8, it does not induce VEGFA mRNA levels on
UPR activation. The reason for this is not known as other UPR targets are clearly
activated in this line and VEGF is induced by hypoxia.
The major function of the UPR is thought to be restoring or maintaining ER
homeostasis in response to an inadequate or toxic environment that adversely affects this
organelle and its ability to fold and assemble proteins. Thus it is perhaps not surprising
that one mechanism for doing this would be to increase the supply of blood flow to the
affected cells so that more nutrients and oxygen can be delivered and waste and other
toxic products could be taken away. In keeping with this possibility, physiological
processes like wound healing require increased vascularization [91], and studies show
evidence of UPR activation in the affected cells [92]. Similarly the placenta must be
highly vascularized in order to supply adequate quantities of oxygen and nutrients to the
developing fetus and to remove toxic waste products. Although there are not data to
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demonstrate that the UPR is normally activated in the developing trophoblasts, a recent
report found that Ire1 was required for normal placenta vascularization and fetal
development [65]. This aspect of the UPR might also be used in pathological conditions
like cancer [93, 94] and ischemia [95] to stimulate angiogenesis, as in both cases there is
evidence of UPR activation [52]
We focused our further analysis on VEGFA because it is the best characterized
and most potent endothelial growth factor that promotes angiogenesis and is a target of
cancer therapy. Recently a study has shown that VEGFA mRNA can be up-regulated in
cultured cells by the UPR inducers, thapsigargin and tunicamycin [81]. We confirmed
the role of the UPR in up-regulating VEGFA expression in various cell lines and also
shown that the UPR is a much better inducer of VEGFA mRNA than hypoxia in a number
of transformed and non-transformed cell lines, further arguing that this represents a
normal function of the UPR. We next focused our attention on the mechanism of
increased VEGFA mRNA expression via UPR and hypoxia signaling pathways using the
C6 rat glioma cell line. The UPR increases VEGFA mRNA stability as well as the
transcription rate of the gene to an even greater extent than that achieved with hypoxia.
Several stress-activated protein kinases, including AMPK, have been reported to increase
VEGFA mRNA stability. The activation of the AMP kinase has been linked to low
glucose levels that result in diminished ATP production [96]. In addition to nutrient
deprivation, other metabolic stresses such as hypoxia, oxidative stress and exercise lead
to activated AMPK [97]. In DU145 prostate carcinoma cells cultured without glucose,
JNK was shown to act upstream of AMPK pathway to increase VEGFA mRNA stability
[87]. However, in our analysis of the C6 cells treatment with SP600125 the JNK
inhibitor had no effect on VEGFA mRNA stability, whereas treatment with the AMPK
inhibitor enhanced its stability in response to both thapsigargin and no glucose,
suggesting that conventional UPR inducing agents can also activate AMPK.
Next, we assessed the importance of the major UPR-induced transcription factors
(i.e., XBP-1(S), ATF4 and ATF6) in mediating VEGFA transcription. Most recently,
Ghosh R et al [81], demonstrated that Ire1 null MEFs, which cannot splice XBP-1 and
induce its downstream targets, have a significant reduction in VEGFA mRNA expression
compared to the Ire1 wild-type cells when treated with thapsigargin. Using a
VEGFA-promoter-luciferase assay and chromatin immunoprecipitation they also showed
that exogenously supplied XBP-1 can bind to the VEGFA promoter and up-regulate
VEGFA mRNA expression. Our studies reveal direct binding of endogenous XBP-1 to
two distinct sites in the rat VEGFA promoter in response to ER stress. Our qRT-PCR
data showed an increase in the VEGFA transcription rate in the XBP-1 wild-type cells
treated with various UPR inducers compared with the XBP-1 null cells. The increased
levels of VEGFA mRNA observed in the wild-type cells was primarily due to an increase
in the transcription rate of the gene, since these inducers had little effect on the stability
of VEGFA transcript in this cell line (data not shown). Previously published data showed
that tumors derived from U87 cells expressing an Ire1 dominant negative construct
developed smaller tumors with decreased vascularization as compared to tumors from
control cells [98]. In addition to this study, two independent reports have also
demonstrated a role for XBP-1 in tumor establishment, growth and angiogenesis [99,
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100]. However, the former study found that when XBP-1 deficient cells are treated with
extreme hypoxia/anoxia (pO2 < 0.02 %) in vitro, there is no defect in secretion of the
proangiogenic factors, VEGFA and bFGF, as compared to wild-type cells. As these
extremely low O2 conditions would be expected to induce both the UPR and the HIF
pathways, it is conceivable that in the absence of XBP-1, HIF1α and 2α are able to
compensate. In support of this possibility, there are HIF binding sites in close proximity
with the XBP-1 “A” site occupied in response to ER stress (Figure 2-4B) in all three
species. As tumor cells, ischemic tissue, and wounds are likely to activate both types of
stress pathways, it will be important to understand the overlap and relative contribution of
each factor in a physiological setting.
Several studies have demonstrated a role for ATF4 in mediating expression of
VEGFA in response to various stimuli such as homocysteine [101], arsenite [102],
oxidized phospholipids [103], and osteopontin [104]. Arsenite is an oxidative stressor
that stimulates ATF4 binding to the VEGFA promoter in a human retinal pigment
epithelial cell line at position +1767 relative to the transcription start site [102]. Similar
observations by another group demonstrated that ATF4 binds to the same AARE site in
the VEGFA promoter when a human umbilical vein endothelial cell line was stimulated
with oxidized phospholipids [103]. These results are in accordance with data published
by Ghosh et al reporting a PERK-ATF4 dependent up-regulation of VEGFA expression.
Using both PERK and ATF4 null MEFs treated with thapsigargin, they showed that
VEGFA mRNA levels were decreased as compared to the corresponding wild-type
MEFs, and demonstrated binding of ectopically expressed ATF4 to the VEGFA promoter
in cells treated with thapsigargin. Using ChIP assays, we confirmed that ATF4
contributes to VEGFA transcription and furthermore demonstrated that endogenous ATF4
binds to a region ~ +0.9kb downstream of the transcription start site in mouse cells when
treated with a UPR inducer.
Lastly, our data suggests that ATF6 does not play a significant role in directly
mediating VEGFA mRNA expression. We observed a modest increase in VEGFA
mRNA in the ATF6 wild-type MEFs compared to the ATF6 null cells when treated with
thapsigargin but not the other stressors. This induction was most likely due to an increase
in the XBP-1(S) protein levels observed only in thapsigargin-treated ATF6 wild-type
cells. The VEGFA promoter-reporter assay performed by Ghosh et al, showed that
over-expression of the transcription factor ATF6 increases luciferase activity ~6 fold
compared to empty vector. The reporter construct used in this assay was derived by
inserting ~1kb of the sequence upstream of the mouse VEGFA transcription start site, in
front of the luciferase gene. Using two different programs to identify transcription factor
binding sites in this region of the mouse VEGFA promoter, we were unable to identify
any potential ATF6 sites. However, this region contains a potential binding site for
XBP-1, which this group reported could bind to ectopically expressed XBP-1 using ChIP
assays. However, we were unable to detect binding of endogenous XBP-1 to this same
site (data not shown).
In addition to the role of UPR-inducible transcription factors in mediating VEGFA
expression, there are data showing that the stress inducible ER chaperone
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ORP150/GRP170 plays a role in post-translational processing/secretion of VEGFA [15].
Ectopic expression of ORP150 in C6 cells increased VEGFA secretion, whereas
decreasing ORP150 levels with an antisense construct resulted in the retention of VEGFA
in the ER. Furthermore, tumors arising from the antisense ORP150 C6 glioma
transfectants demonstrate an initial phase of growth comparable to the wild-type glioma
cells which was followed by marked regression and decreased angiogenesis within 8
days. Our analysis of VEGFA secretion in C6 cells revealed that although hypoxia and
tunicamycin lead to similar increases in VEGFA mRNA, that more VEGFA was secreted
from the tunicamycin treated cells, which had higher levels of ORP150/GRP170 mRNA
and protein levels. This correlation is further underscored by the finding that although
thapsigargin was the strongest inducer of VEGFA mRNA, it caused a less robust upregulation of GRP170 and less VEGFA was secreted from thapsigargin treated cells than
from either tunicamycin or no-glucose treated cells.
In conclusion, using microarray analysis we found a significant up-regulation of a
large proportion of positive regulators of angiogenesis in response to ER stress and
verified four of these using qRT-PCR assays. Our studies revealed that in some cell lines
UPR activation enhanced VEGFA mRNA and protein expression more potently than
hypoxia and that this was achieved through a combination of transcriptional as well as
post-transcriptional mechanisms. Thus, the UPR is likely to be an important regulator of
angiogenesis in normal physiological settings as well as pathological conditions like
cancer and ischemia and may synergize with the well-studied HIF pathway activated by
hypoxia.
Materials and Methods
Cell culture and stress induction
Daoy human medulloblastoma cell line [105], C6 rat glioma cell line [106],
XBP-1 wild-type and null MEFs, ATF6 wild-type and null MEFs, and NIH3T3 mouse
fibroblasts were maintained in DMEM supplemented with 10% fetal bovine serum, 2
mM glutamine and 1% antibiotic-antimycotic at 37ºC in a 5% CO2 incubator. NB1691
and SKNAS human neuroblastoma cell lines were cultured in RPMI 1640 supplemented
with 10% fetal bovine serum and 2 mM glutamine. Primary wild-type and ATF4 null
MEFs were propagated in cell culture as previously described [26]. Cells were plated
and left untreated (NT) or treated with thapsigargin (Tg, 1 µM), tunicamycin (Tm, 2.5
µg/ml), homocysteine (HCys, 10 mM), CoCl2 (100 μM), media lacking glucose (No Glu)
(DMEM cat.no.11966-GIBCO and RPMI cat. no.11879-GIBCO), or cultured in a
hypoxia chamber containing 1% O2 for the indicated periods of time.
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mRNA and hnRNA quantification by qRT-PCR
Total RNA was extracted using the RNeasy Qiagen mini-prep kit according to the
manufacturer’s protocol. RNA samples were subjected to qRT-PCR, and reactions were
done in duplicate using a TaqMan One-Step PCR Master Mix kit. Amplification of the
corresponding genes was achieved using specific primers and probe set and measured
continuously using an ABI 7900 HTI Detection System. Where indicated, VEGF hnRNA
was measured using qRT-PCR primers and probe across intron 1 and exon 2, for the rat
gene and across exon 3 and intron 3, for the mouse gene. The signal obtained for
measuring both, mRNA and hnRNA, was compared relative to 18S rRNA internal
control. A recent study detected down-regulation of ribosomal RNA by ER stress [107].
However, in our study the 18S rRNA cycle threshold (Ct) values obtained by qRT-PCR
remained relatively unchanged in the presence of ER stress arguing that 18S rRNA levels
were not changing with the conditions used. The value for untreated cells was set to 1
and the value for the various treatments was presented as a fraction of this number. In the
case of wild-type and null cells, the untreated value for each cell type was set to 1 unless
otherwise indicated.
mRNA stability assay
C6 cells were pre-incubated in normal complete media, media containing
thapsigargin or no glucose, or in a hypoxia chamber for 6 hours. Actinomycin D (5
g/ml- Sigma Aldrich) was added to each test set, and the cells were reincubated for the
indicated times. Total RNA was extracted and VEGF mRNA was analyzed by
qRT-PCR.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) analysis was performed using a ChIP kit
(Upstate Biotechnology) according to the manufacturer’s instructions. Briefly, cells were
incubated for the indicated times with or without different stress inducers. Formaldehyde
was then added (final concentration, 1 %), and cells were incubated for 10 minutes at
room temperature to stabilize DNA-protein interactions. Cross-linking was stopped by
the addition of glycine (final concentration, 0.125 M). Cell extracts were sonicated with a
Branson Sonifier 250 (VWR) for 5 bursts at 10 seconds each at 20 % power output to
shear DNA to 1kb or less. Extracts from 107 cells were incubated overnight with
antibodies against ATF4 generously provided by Dr. David Ron (University of
Cambridge, U.K.), rabbit anti-XBP-1(S) polyclonal antiserum (Santa Cruz Biotechnology
sc-7160X) or rabbit anti-BiP polyclonal antiserum [108], which served as a negative
control. Two percent of the extract volume was removed before immunoprecipitation and
served as input control. DNA fragments from immunoprecipitated complexes and input
controls were released by heating at 65ºC overnight and purified using the PCR
purification kit (QIAquick, Qiagen) according to the manufacturer’s protocol. Purified
immunoprecipitated DNA and input DNA were then analyzed by PCR.
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Western blotting
For Western blotting cells were lysed in Nonidet P-40 lysing buffer (50 mM
Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% Nonidet P-40, and 0.5 % deoxycholic acid) for
30 minutes on ice. The proteins were electrophoresed under reducing conditions,
transferred to a PVDF membrane and probed with the indicated primary antibodies:
Rabbit anti-XBP-1(S), rabbit anti-ATF4, goat anti-Hsc70, and goat anti-Lamin B1 were
purchased from Santa Cruz Biotechnology, mouse anti-HIF1α and mouse anti-BNIP3
from Abcam, and rabbit anti-phosho-AMP kinase from Cell Signaling. Rabbit anti-CHOP
has been described previously [56]. Isolation of nuclear and cytosolic fraction for
detecting HIF1α by Western blotting was performed as previously described [109]. Blots
were incubated with the appropriate HRP-conjugated secondary antibody, and proteins
were visualized using the Pierce enhanced chemiluminescent substrate (Thermo
Scientific).
Microarray gene expression analysis
Total RNA (5-10μg) was processed according to the Affymetrix eukaryote
one-cycle target labeling protocol at the Hartwell center microarray core at St Jude
Children’s Research Hospital. Biotin-labeled cRNA (15μg) was hybridized overnight at
45ºC to the human HG-U133 Plus 2.0 GeneChip array, which interrogates more than
54,000 human transcripts and ESTs. After staining and washing, arrays were scanned and
expression values summarized using the MAS5 algorithm as implemented in the GCOS
v1.4 software (Affymetrix, Santa Clara, CA). Signals were normalized for each array by
scaling to a 2% trimmed mean of 500. Detection calls (Present, Absent and Marginal)
were determined using the default parameters of the software. Signal values were
log2-transformed prior to analysis. Differential expression between thapsigargin-treated
and untreated cells was determined from two independent experiments using the Local
Pooled Error t-test(1) (S-Plus 6.2, TIBCO, Palo Alto, CA). False discovery estimates
were calculated as described [110]. Hierarchical clustering was performed using the
Spotfire Decision Site 9.0 software (TIBCO). Probe set annotations were obtained from
the Affymetrix website. Gene ontology and network analysis was performed using
Metacore from GeneGo Inc. (St. Joseph, MI). All data is MIAME compliant, and the raw
data has been deposited in GEO, a MIAME compliant database, accession number:
GSE21979.
Statistical analysis
All results are expressed as mean values plus or minus SD from triplicate
measurements performed in 2 to 4 independent experiments producing similar results.

35

CHAPTER 3.

ROLE OF THE UPR AND HIF SIGNALING PATHWAYS IN
REGULATING VEGF EXPRESSION
Introduction

Solid tumors contain regions that are poorly oxygenated due to a limited
accessibility to functional blood supply. These areas are extremely heterogenous and
very dynamic in an individual tumor and between tumors in a given patient. Hypoxia is
an important factor that determines prognosis for patients, because it has the ability to
alter the cellular metabolism and cause resistance to radiotherapy and chemotherapy.
Hypoxic cells are more resistant to radiation therapy compared to well-oxygenated cells,
because oxygen is required for the induction of DNA damage by radiation [111]. The
poorly vascularized, hypoxic regions of the tumor are also resistant to chemotherapeutic
agents due to inefficient drug delivery by distantly located blood vessels. Clinical
evidence suggests that hypoxia not only alters the therapeutic outcome of the patient but
also contributes to a more aggressive tumor phenotype. The use of mouse models in
tumor biology has enabled us to understand some important aspects of tumor
oxygenation. First, the severity of hypoxia can vary from completely anoxic (extreme
hypoxia) to mildly hypoxic or even normoxic regions in the tumor. The variations
observed in the pO2 in different regions of the tumor is largely due to the transient
changes in blood flow and the inability of blood vessels to fuel the rapidly expanding
tumor mass. Second, the oxygenation status of any tumor cell is highly dynamic due to
the disorganized architecture of tumor blood vessels and rapid vasoconstriction and
dilation of the vasculature. These patterns of oxygenation have very different biological
and clinical implications, as varying amounts of oxygen levels in the cell have the ability
to activate cytoprotective stress signaling pathways [112, 113].
The normal atmospheric concentration of oxygen (normoxia) is 21 % or 160 mm
Hg. Measurements of oxygen levels in animal models have demonstrated that the pO2 in
regions of the tumor at a distance of greater than 100 μm from a vessel can vary from 10
mm Hg (hypoxia) to nearly 0 mm Hg (anoxia). Studies with cultured cells have revealed
that when oxygen levels drop below 5% O2 or 38 mm Hg, the hypoxia-inducible factor
(HIF) pathway is activated [114]. Transcriptional responses to hypoxia are largely
regulated by HIF, a heterodimeric protein composed of an oxygen-labile  subunit and a
constitutively expressed  subunit. There are two  subunit members, HIF1 and
HIF2, which are continuously synthesized and rapidly degraded under normal
physiological conditions [115]. The oxygen-dependent degradation of the HIF--subunit
is mediated by hydroxylation of proline 402 and proline 564 by prolyl hydroxylase
domain protein 2. Hydroxylated HIF- binds to von Hippel Lindau tumor suppressor
protein (VHL), which then targets the α subunit for degradation via the 26S proteasome
[10]. The decrease in oxygen levels that occurs with increasing distance from a blood
vessel also correlates with a decrease in the environmental pH. The decreased pH
observed in tumor tissues is due to an increase in the glycolytic rate of cancer cells. As
cancer cells shift their metabolism to glycolysis from oxidative phosphorylation, due to
the decreased availability of oxygen, there is an increase in the production of lactate,
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which is secreted into the extracellular space making the tumor microenvironment more
acidic [116].
Several more recent studies have demonstrated that extreme hypoxia (<0.02 %
O2) can also activate the UPR [117, 118], which enables the cell to adapt to the
suboptimal conditions for protein folding by decreasing the overall rate of protein
synthesis. Secreted and membrane proteins are processed in the endoplasmic reticulum
where they encounter molecular chaperones and folding enzymes, like protein disulfide
isomerases, that catalyze the formation of disulphide bonds. These bonds serve to
stabilize both folding intermediates and the mature protein, but the enzymatic reaction
that catalyzes their formation requires molecular oxygen. Hence, limiting amounts of
oxygen in the cell can impinge on the protein folding capacity in the ER, leading to the
accumulation of unfolded proteins and activation of the UPR [16]. The change in the pH
of the tumor microenvironment that occurs in response to the shift to glycolytic
metabolism also has the ability to contribute to UPR activation. The reduced pH can
change the net charge on the side chains of amino acids, which play a major role in
defining folding pathways. The high metabolic rate of many tumor cells put additional
demands on the folding capacity of the ER and provides yet another stimulus for UPR
activation. Thus, within a tumor mass it is likely that individual cells are likely to have
different compliments of these two stress signaling pathways, with some cells having
only one of them activated and others having both.
The HIF pathway is well documented to play a significant role in the production
of VEGF in cultured cells and in promoting angiogenesis in animal models. VEGF is a
potent proangiogenic factor required for proliferation and migration of endothelial cells
that enables formation of new blood vessels. In vivo studies reported that HIF1-/embryonic stem cell derived tumors had fewer blood vessels and impaired vasculature
within the tumor mass as compared to the control wild-type counterparts [119]. The
importance of the hypoxia-inducible transcription factors, HIF1 and HIF2, in
regulating VEGF expression was further emphasized from complete knockout
experiments. Both, HIF1 and HIF2 knockout animals are embryonic lethal due to lack
of functional vasculature [119, 120]. More recently, we [49], and others [121], have
shown that the UPR also plays an important role in regulating VEGF expression at both
transcriptional and post-transcriptional levels in cultured cells. While we wish to
ultimately assess the contribution of the UPR to tumor angiogenesis, due to the
heterogeneous nature of tumors, it is critical that we first understand the relative
contribution of the UPR and HIF signaling pathways when experienced alone and in
combination, in regulating VEGF expression using carefully defined conditions that are
specific to each of these stress pathways.
Due to the large variety of knockout lines available, in our previous study we used
a combination of rodent cell lines to identify critical elements of the UPR. We
demonstrated that both XBP-1(S) and ATF4 bound to the VEGF promoter and
contributed to VEGF expression. However, the exact contribution of these two factors
could not be determined, because the corresponding controls for the various mouse
knockout cell lines had different basal and stress induced levels of VEGF mRNA and
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protein. To remedy this problem and to determine the significance of the UPR in
regulating VEGF expression in human tumor cell lines, we identified two human
neuroblastoma cell lines, SKNAS and NB1691, which have low basal levels of VEGF
expression that are significantly induced by ER stress. Similar to the studies in rodent
cells, we were able to detect both XBP-1(S) and ATF4 bound to the human VEGFA
promoter in a stress-inducible manner. Using siRNA in transient expression experiments,
we reduced the expression of both XBP-1(S) and ATF4 independently and found that
ATF4 plays the predominant role in regulating VEGF expression in response to UPR
activation in human cells. Thus, we have engineered these two neuroblastoma lines to
inducibly express shRNA to ATF4. In addition, clones that stably express shRNA to
HIF1α have been obtained for both cell lines. In preliminary experiments, we found that
there is a synergy between the two pathways, as VEGF expression is significantly higher
when cells are exposed to both stresses simultaneously. However, although ATF4 plays
a major role in regulating VEGF expression in cells experiencing only ER stress, it does
not contribute significantly to its expression when the UPR and HIF pathways are
activated together in cell culture experiments. Instead, the UPR appears to enhance
HIF1 activity and result in HIF1-dependent increases in the expression of VEGF and
other HIF targets via an as yet undetermined mechanism. The neuroblastoma cell lines
expressing inducible stable ATF4 shRNA will be useful in animal experiments to
determine the contribution of this factor at various time points during the course of tumor
development.
Results
Defining culture conditions that are specific to HIF and UPR pathways
To determine the contribution of the UPR versus the HIF pathway in regulating
VEGF expression in human neuroblastoma cell lines, it was critical to identify conditions
that would activate each pathway without affecting the other. This was particularly
important, since extreme hypoxia has been reported to activate not only the HIF pathway
but also the UPR [117, 122]. In addition, we wished to use more physiological activators
of the UPR instead of the more traditional pharmacological activators, like thapsigargin
or tunicamycin. SKNAS and NB1691 human neuroblastoma cells were treated with
media containing decreased concentrations of glucose to mimic a physiological stress
experienced by tumors. Under non-stressed conditions, regular tissue culture media
contains 25 mM glucose. A variety of concentrations were tested, but we chose 1 mM, a
concentration that readily activated the UPR, was not toxic to cells, and is likely to mimic
conditions encountered by tumor cells [123]. The two lines were treated with low
glucose for 8 and 16 h and the effects on UPR targets and HIF targets were assessed by
real-time PCR. The cell lines were also incubated in a hypoxia chamber containing 1%
O2 to activate the HIF signaling pathway. In both cells lines, low glucose lead to the upregulation of GADD34, a transcriptional target of ATF4 that is activated downstream of
PERK (Figure 3-1A and C), whereas incubating the cells in 1% O2 had no affect on this
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Figure 3-1. Low glucose activates the UPR but not the HIF signaling pathway and
1% O2 (hypoxia) activates the HIF pathway but not the UPR. Cells were either left
untreated (NT), incubated in media containing 1 mM glucose (Lglu), or treated in a
hypoxia chamber containing 1% O2 for 8 hours and 16 hours as indicated. Total RNA
from the indicated samples was subjected to qRT-PCR to quantify Gadd34 mRNA
(A{SKNASluc} and C{NB1691luc}) or BNIP3 mRNA (B{SKNASluc} and
D{NB1691luc}) at the indicated time points. RNA levels were expressed relative to the
control untreated samples for each line, which was set to 1. Experiments were performed
in duplicate (values are mean ± SD).
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target. Similarly, when the cells were cultured in 1% O2, the HIF target, BNIP3, was
readily induced, but there was no up-regulation of the UPR target, GADD34 (Figure
3-1B and D). Thus, it was possible to define conditions that were specific for each of the
two stresses.
UPR and HIF activation induces VEGF secretion
We next measured the effect of these pathways on VEGF secretion using the
stress conditions described above that activated either the HIF or UPR alone without
affecting the other pathway. Although there was a detectable amount of VEGF secreted
from untreated cells, we observed an increase of VEGFA in the media from cells treated
with either of the stress inducers (Figure 3-2). Culturing cells in low glucose media for 16
hours caused a 3-fold increase in VEGF secretion as compared to the untreated control
sample in the SKNASluc line. Hypoxia seemed to be a somewhat more potent inducer of
VEGF secretion in this line, as 16 hours of treatment in the hypoxia chamber resulted in a
~5-fold increase as compared to the control sample. When the cells were treated with a
combination of both stresses; hypoxia and low glucose media, we observed an increase in
VEGF secretion that was somewhat greater than what was seen with either of the stress
conditions alone (Figure 3-2).
UPR and HIF signaling pathways have a synergist effect on VEGF transcription
Since both pathways are known to regulate VEGF at the transcriptional level, we
determined the relative contribution of the UPR and HIF signaling pathways in regulating
both the transcription rate and steady state mRNA levels. VEGF hnRNA levels were used
as a measure of the transcription rate of the gene. The VEGF transcription rate was
increased 3-fold in SKNASluc cells treated with low glucose media for 8 hours, which
was increased further after 16 hours (Figure 3-3A). Hypoxia induces VEGF transcription
rate 4 fold at both, 8 and 16-hour time points. The combination of both UPR and HIF
activation results in an increase in VEGF hnRNA levels to 7-fold at 8 hours, and after
16 hours the combination of these two stress pathways appeared synergistic and induced
the VEGF transcription rate 12-fold. The VEGF mRNA levels were induced 2 fold in
SKNASluc cell line after 8 and 16 hours of treatment in media lacking glucose (Figure
3-3B). In keeping with the increased transcription rate observed with the combination of
UPR and HIF activation, we found an additive effect on up-regulation of VEGF mRNA
levels in the line at both time points. The NB1691luc cell line had a similar pattern of
VEGF hnRNA and mRNA induction with UPR and HIF activation at both time points.
VEGF expression was induced 4 fold with each of these pathways activated alone at
both time points as indicated in Figure 3-2C and D. However, the combination of both
stresses had a more potent and synergistic effect on up-regulating VEGF expression,
particularly in the NB1691 cell line.
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Figure 3-2. VEGF secretion is increased with UPR and HIF activation.
SKNASluc cells were either left untreated (NT), incubated in media containing 1 mM
glucose (Low Glu), treated in a hypoxia chamber containing 1% O2 (Hypoxia 1% O2) or
treated with a combination of low glucose media and incubated in a hypoxia chamber
(Low Glu 1 mM+Hypoxia 1% O2) for 8 hours and 16 hours as indicated in the figure.
Conditioned media was collected from the indicated samples at the given time points and
analyzed for VEGF secretion by ELISA. Experiments were performed in duplicate
(values are mean ± SD).
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Figure 3-3. VEGF mRNA and hnRNA levels are up-regulated with the UPR and
HIF signaling pathways alone and more potently with the combination of both
stresses together. Cells were either left untreated (NT), incubated in media containing 1
mM glucose (Low Glu), treated in a hypoxia chamber containing 1% O2 (Hypoxia 1%
O2) or treated with a combination of low glucose media (1 mM) and incubated in a
hypoxia chamber (Low Glu 1 mM+Hypoxia 1% O2) for 8 hours and 16 hours as
indicated in the figure. Total RNA from the indicated samples was subjected to qRT-PCR
to quantify VEGF hnRNA (A {SKNASluc} and C {NB1691luc}) or VEGF mRNA
(B{SKNASluc} and D{NB1691luc}) at the indicated time points. RNA levels were
expressed relative to the control untreated samples for each line, which was set to 1.
Experiments were performed in duplicate (values are mean ± SD).
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Human VEGF promoter has potential binding sites for both UPR-inducible and
HIF transcription factors
We next analyzed 10kb upstream and 3 kb downstream of the transcription start
site of the human VEGF promoter for potential binding sites of UPR-inducible
transcription factors, XBP-1(S) and ATF4 and hypoxia-inducible HIF. A number of
potential binding sites were identified for each of these factors as illustrated in Figure
3-4. Under hypoxic conditions, HIF1α rapidly accumulates, dimerizes with HIF1β, and
binds to the core DNA binding sequence 5’-RCGTG-3’ (R, purine (A or G)) on target
genes. On the other hand, upon UPR activation XBP-1(U) is spliced to form the activated
form; XBP-1(S), which translocates to the nucleus and binds to core DNA sequence
5’-ACGTG-3’. Upon UPR activation, ATF4 is translated and binds to its target genes
containing the core 5’-CGTXA-3’ (X= C or A) sequence. Inspection of the human VEGF
promoter indicated that several of the potential UPR-inducible transcription factor sites
overlapped with possible HIF binding sites. Thus, we first tested occupation of these sites
when each pathway was activated alone.
ATF4 and XBP-1 bind to the human VEGF promoter in response to UPR activation
and HIF1α binds in response to hypoxia
To determine if either of the UPR induced transcription factors binds to the
human VEGFA promoter in response to ER stress, we performed ChIP assays in the
SKNAS, NB15 and NB7 cell lines. We were unable to detect binding of ATF4 to any of
the six potential sites upstream of the transcription start site in response to low glucose
treatment (data not shown). However, we did detect UPR-stress-inducible binding of
ATF4 to a site at position +1.2 kb relative to the transcription start site (Figure 3-5D),
which is analogous to where ATF4 binds in the mouse promoter. We also performed
ChIP assays in the human neuroblastoma cell lines, NB7 and NB15, and were able to
detect binding of XBP-1(S) at a region 0.5 kb upstream of the transcription start site after
treatment with the UPR inducer, thapsigargin (Figure 3-5E). Promoter analysis of the
human VEGFA gene revealed several potential HIF binding sites (Figure 3-5C). It has
been reported in the literature that HIF1α binds to the human VEGF promoter -900 bp
relative to the transcription start site in response to hypoxia [8]. We performed ChIP
assays in the SKNAS cell line to determine if this site and the other potential HIF binding
sites are occupied with hypoxia (1% O2). We detected a slight but reproducible binding
of HIF1α to a region on the human VEGF promoter -900bp relative to the transcription
start site in response to hypoxia (Figure 3-5F), but were unable to detect HIF1α to any of
the other potential binding sites on the promoter.
ATF4 plays a major role in regulating UPR-induced VEGF secretion in SKNASluc
cells
Chromatin immunoprecipitation studies performed in the human neuroblastoma
cell lines demonstrated that ATF4 and XBP-1(S) bind to the human VEGF gene on UPR
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Figure 3-4. Potential binding sites for XBP-1, ATF4 and HIF1 on the human
VEGF promoter. Potential binding sites of UPR downstream transcription factors in
human VEGF promoter. The online software rVista was used to identify potential
binding sequences of transcription factors, XBP-1 (cyan), ATF4 (green) and HIF (red) in
a region 10 kb upstream and 3 kb downstream of the transcription start site (TSS) on the
human VEGFA promoter.
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Figure 3-5. UPR-inducible transcription factors, ATF4 and XBP-1(S) bind to the
human VEGF promoter in response to UPR activation and HIF1α binds in response
to hypoxia. Potential ATF4 (A), XBP-1(S) (B) and HIF (C) sites in the human VEGF
promoter. Cross-linked chromatin from SKNAS cells that were untreated (NT),
incubated in media containing 1 mM glucose (Lglu) or treated in a hypoxia chamber
containing 1% O2 for 8hours were immunoprecipitated with anti-ATF4 (D) or anti-HIF1α
(F). Human neuroblastoma cell lines, NB7 and NB15 either left untreated or treated with
thapsigargin, were used in ChIP assays with anti-XBP-1(S) antibody (E). Immunoprecipitated chromatin and input controls were used for PCR amplification.
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activation. Our previous study revealed that ATF4 also binds to the mouse VEGF gene
using mouse embryonic fibroblasts deficient in this factor. XBP-1(S) was also shown to
bind to the rat VEGF promoter and using knockout cell lines, and we were able to show
that it plays a role in regulating VEGF expression in cell culture experiments. We were
unable to determine the exact contribution of ATF4 and XBP-1 in regulating VEGF
expression as the untreated wild-type MEFs had different basal levels of VEGF and
induced its expression to different levels [49]. To overcome this problem, we performed
transient siRNA experiments to determine the contribution of these two UPR
transcription factors in the same human cell line. Since it is important to obtain 100% of
the cell population expressing the siRNA, we co-transfected the indicated siRNAs with
FITC-labeled non-targeting RNA and then sorted the samples after 48 hours of
transfection to obtain only the viable FITC positive cells. Cells transfected with siRNA
targeting human ATF4 significantly decreased UPR-induced expression of this factor and
had no significant effect on XBP-1(S) protein levels (Figure 3-6B). In a similar manner,
cells transfected with XBP-1(S) siRNA had significantly decreased expression of
UPR-induced XBP-1(S) protein. Of note, hypoxia (1% O2) did not induce either ATF4 or
XBP-1(S) protein levels (Figure 3-6 B). The culture supernatant from each group was
obtained and used to measure VEGF protein levels by ELISA. VEGF secretion was
measured from the negative control cells, as well as cells treated with ATF4 siRNA or
XBP-1(S) siRNA. Knocking down ATF4 expression significantly reduced VEGF
secretion to the basal level, where as knocking down XBP-1(S) only decreased VEGF
secretion 25% as compared to the negative control-thapsigargin treated sample. These
results suggest that ATF4 is the major regulator for UPR-induced VEGF secretion in the
SKNASluc cell line.
Inducible stable knockdown of ATF4 inhibits VEGF transcription rate in response
to low glucose but not hypoxia or the combination
To further test the role of the UPR-inducible transcription factor, ATF4, in
regulating VEGF expression, we engineered doxycycline-inducible knockdown
SKNASluc lines, and are in the midst of selecting clones for the NB1691 cell line. This
strategy will enable us in the future to manipulate the expression of ATF4 in xenograft
studies at various time points during the course of tumor growth. Single cell clones were
isolated after transfecting with a single shRNA specific for ATF4. The cells were
incubated with dox for 0, 24, 48hr and then treated with thapsigargin for 16 hours. Cell
lysates were prepared and blotted for ATF4 to examine the effects of the shRNA on
ATF4 expression. We also examined cell lysates for XBP-1 expression as a negative
control. Two representative clones were isolated that showed a significant inhibition of
stress-induced ATF4 expression and decreased Gadd34 mRNA levels-a downstream
target of ATF4 (Figure 3-7A and B). When these clones were then examined for the
effects on UPR-induced VEGF transcription, we found that the rates were reduced to
basal levels. As anticipated, decreasing ATF4 expression had no effect in regulating
hypoxia-induced VEGF expression, keeping with the results obtained from the transient
knockdown experiments. Although we started isolating clones with inducible
XBP-1shRNA expression, given the fact that decreasing ATF4 appeared to block the
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Figure 3-6. ATF4 plays an important role in regulating VEGF secretion in
response to UPR activation. SKNASluc cells were either transiently co-transfected with
FITC-labeled non-targeting RNA and siRNA specific for human XBP-1(S) or ATF4 as
indicated in the figure. As a control, cells were transfected with only FITC-labeled
non-targeting RNA. After 48hours, cells were sorted and the FITC positive viable
population was re-plated. 24 hours post-sorting, the cells from each group were either left
untreated, treated with 1μM thapsigargin or incubated in a hypoxia chamber (1% O2). (A)
Conditioned media was obtained from each treatment as indicated in the figure and
analyzed for VEGF secretion by ELISA. (B) Western blot analysis was performed on cell
lysates as indicated in the figure. ATF4 and XBP-1(S) levels were analyzed from nuclear
fractions and Lamin-B1 was used as a loading control.
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Figure 3-7. ATF4 regulates UPR-induced VEGF transcription rate but has no
affect in response to hypoxia or the combination of both the pathways. Two clones
with stable expression of Tet-repressor and pSuperior.puro-ATF4shRNA vectors in the
SKNASluc cell line were obtained. (A) The ATF4shRNA clones were treated with
doxycycline (1μg/ml media) for 24 hours or 48 hours after which the cells were either left
untreated or treated with thapsigargin for 16 hours. Cells were harvested and ATF4
protein levels were measured using western blot analysis. (B) The negative control cell
line and ATFshRNA clones were treated with Dox for 48 hours following which they
were either left untreated or treated as indicated in the figure for 16 hours. Cells were
harvested and RNA was extracted to measure Gadd34 levels- a downstream target of
ATF4. (C) The negative control cell line and ATFshRNA clones were treated with Dox
for 48 hours following which they were either left untreated or treated with low glucose
media (1 mM glucose), incubated in a hypoxia chamber (1% O2) or treated with a
combination of low glucose media and hypoxia for 16 hours. Post-treatment cells were
harvested, RNA was extracted and total RNA from the indicated samples was subjected
to qRT-PCR to quantify VEGF hnRNA. RNA levels were expressed relative to the
control untreated sample, which was set to 1.
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UPR-induced expression of VEGF completely, we did not continue with these.
We next designed an experiment to determine the relative contribution of ATF4 to
VEGF expression when cells have activated both the UPR and HIF pathways
simultaneously. To our surprise, we found that decreasing ATF4 expression had no
perceivable effect in regulating VEGF transcription rate when both, the HIF and UPR
signaling pathways were activated together (Figure 3-7C).
Thus, we first examined ATF4 levels in these clones and assessed the binding
ability of this factor in the presence low glucose or both stresses together. As observed in
the parental line, ATF4 binds to the human VEGF promoter 1.2 kb downstream of the
transcription start site when treated with low glucose media (Figure 3-8B). A somewhat
fainter PCR product for ATF4 binding was detected with a combination of both stresses
together. We also analyzed ATF4 protein levels in the SKNASluc (Figure 3-8C) and
NB1691 (Figure 3-8D) by Western blot analyses. ATF4 protein levels were induced both
with low glucose media, which activates the UPR, as well as with a combination of low
glucose media and hypoxia in both cell lines. However, it must be noted that ATF4
protein levels were decreased in both lines when the two pathways are activated together
as compared to UPR activation alone, particularly at later time points. The ChIP assay
was performed after 8 hours of treatment as indicated in the figure, and at this time point
ATF4 levels appear to be more similar when either the UPR is activated alone or in
combination with hypoxia (Figure 3-8C).
HIF1α binding to the human VEGF promoter appears greater with the combination
of hypoxia and low glucose
We repeated ChIP assays in the SKNASluc to determine if this site and the other
potential HIF binding sites are occupied with hypoxia alone and the combination of
hypoxia and low glucose together. We detected hypoxia-inducible binding of HIF1α to
the region on the human VEGF promoter -900bp relative to the transcription start site
(Figure 3-9B). We were also able to detect binding of HIF1α with the combination of
hypoxia and low glucose, which appeared to be somewhat stronger, although this has not
been repeated using quantitative PCR analysis, which we will do in our follow-up
studies. We also analyzed HIF1α protein levels in the SKNASluc (Figure 3-9C) by
Western blot analyses. HIF1α protein levels were induced with hypoxia, however, unlike
ATF4, the combination of low glucose media and hypoxia reproducibly lead to somewhat
similar levels of HIF1α.
HIF1α regulates VEGF transcription rate in response to hypoxia and the
combination of both stresses together
Our ATF4 knockdown experiments argued that ATF4 did not appear to contribute
to VEGF expression with the combination of low glucose and hypoxia. This could
suggest that another UPR-induced transcription factor played a bigger role with the
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Figure 3-8. UPR-inducible transcription factor, ATF4, binds to the human VEGF
promoter. (A) Potential ATF4 sites in the human VEGF promoter. (B) Cross-linked
chromatin from SKNASluc cells that were untreated (NT), incubated in media containing
1 mM glucose (Lglu), treated in a hypoxia chamber containing 1% O2 or treated with a
combination of low glucose media and incubated in a hypoxia chamber (Hyp+Lglu) for
8hours were immunoprecipitated with anti-ATF4. Immuno-precipitated chromatin and
input controls were used for PCR amplification. As a positive control, primers spanning
the ATF4 binding region on the CHOP promoter were used to PCR amplify the antiATF4 precipitated chromatin. ATF4 protein levels were detected in SKNASluc (C) and
NB1691luc (D) cells treated with low glucose (1 mM), hypoxia or Low glucose +
Hypoxia using Western blot analysis.
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Figure 3-9. HIF1α binds to the VEGF human promoter when the HIF signaling
pathway is activated alone and in combination with the UPR. (A) Potential HIF sites
in the human VEGF promoter. (B) Cross-linked chromatin from SKNASluc cells that
were untreated (NT), incubated in media containing 1 mM glucose (Lglu), treated in a
hypoxia chamber containing 1%O2 or treated with a combination of low glucose media
and incubated in a hypoxia chamber (Hyp+Lglu) for 8 hours were immunoprecipitated
with anti-HIF1α. Immuno-precipitated chromatin and input controls were used for PCR
amplification. (C) HIF1α protein levels were detected in SKNAS cells treated with Hyp
and Hyp+Lglu using Western blot analysis.
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combination of stresses. Thus, we first wished to determine the contribution of HIF1α in
regulating VEGF transcription rate. To do so, we analyzed SKNAS cells that have stable
expression of HIF1α shRNA. As anticipated, the VEGF transcription rate was decreased
to basal levels in the cells expressing HIF1α shRNA were incubated in a hypoxia
chamber compared to the control line, whereas there was no effect on UPR induced
expression. However, we found that the VEGF transcription rate was reduced to near
basal levels in the HIF1α shRNA cells when they were treated with the combination of
hypoxia and low glucose as compared to the negative control (Figure 3-10A). This
argued that instead of both stress-regulated transcription factors playing a joint role in
increasing VEGF transcription that the UPR was somehow increasing either HIF
expression or activity.
As this had not been reported previously to our knowledge, we wished to
determine how the UPR was affecting HIF. Although HIF is not induced at the
transcriptional level in response to hypoxia, we reasoned that if the UPR either led to
increased HIF mRNA by either increasing its transcription or stability, that there might be
a larger pool of HIF protein to be stabilized by ER stress. Therefore, we first measured
HIF transcription rate with both stresses alone and the combination. Although HIF
transcription rate was not induced with hypoxia alone at either of the time points we
analyzed, there was a modest (~2 fold) but reproducible increase in the HIF transcription
rate when both stress pathways were activated together (Figure 3-10B). These results
suggest that the UPR might synergize with the HIF pathway by up-regulating HIF1α
transcription. Further studies in other lines and at addition time points will be required to
determine if indeed HIF1α is a transcriptional target of the UPR.
Lactate production is inhibited in SKNASluc cells treated with low glucose and the
combination of low glucose + hypoxia
A second possibility for the observed synergy relates to the mechanism used by
tumor cells to produce energy. Due in part to limited availability of oxygen, cancer cells
generate ATP through a less efficient mechanism compared to normal differentiated cells
by increasing glycolysis and decreasing oxidative phosphorylation. This switch in
metabolism is known as the Warburg effect. By decreasing glucose, which is necessary
for glycolytic energy production, we reasoned that perhaps when oxygen levels were also
limited in our experimental set up, it was possible that the cells would be forced to
continue using oxidative phosphorylation and thus become more hypoxic then when
similar levels of oxygen were encountered alone, which could result in more HIF activity.
As a somewhat indirect method of testing the possibility that the combination of these
stresses could increase the hypoxic state of the interior of the cells, we measured lactate
production from the SKNASluc treated with various UPR inducers, with hypoxia alone,
and with the combination (Figure 3-11). Lactate secretion gives us a measure of the
amount of glycolysis occurring in the cell, because glucose is broken down via multiple
steps to pyruvate and finally converted to lactate as the end product. We observed a
relatively high basal level of lactate secretion in the untreated cells, suggesting that they
were already using some glycolysis to produce energy. This is a common feature of
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Figure 3-10. HIF1α regulates VEGF transcription rate in response to HIF
signaling and the combination of UPR and HIF signaling. (A) SKNAS cells that have
stable expression of either HIF1α shRNA or control shRNA were either left untreated
(NT), incubated in media containing 1 mM glucose (Low Glu), treated in a hypoxia
chamber containing 1% O2 (Hyp) or treated with a combination of low glucose media (1
mM) and incubated in a hypoxia chamber (Hyp+Lglu) for 8 hours as indicated in the
figure. Total RNA from the indicated samples was subjected to qRT-PCR to quantify
VEGF hnRNA. RNA levels were expressed relative to the control untreated samples for
each line, which was set to 1. (B) SKNASluc cells were treated with low glucose media,
hypoxia and the combination of both stresses for 8 and 16 hours as indicated in the
figure. Total RNA was extracted and subjected to qRT-PCR to quantify HIFhnRNA
levels.
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Figure 3-11. Lactate production from SKNASluc cells treated with UPR inducers
and hypoxia. SKNASluc cells were either left untreated or treated with thapsigargin
(Tg1 μM), low glucose media (1 mM), hypoxia (1% O2) or a combination of Tg and
hypoxia or Low glucose media and hypoxia for various time points as indicated in the
figure. Post-treatment cells were harvested, media was collected, de-proteinized using a
10 kD spin column and used to measure lactate production. Lactate is represented as
mmol secreted per 1x106 cells.
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cancer cells. As anticipated, lowering the glucose levels resulted in decreased secretion of
lactate at all times points, whereas treating cells with thapsigargin, another UPR inducer
which was not expected to affect cellular glucose levels, had no effect on lactate
production. Although we anticipated that incubating cells in hypoxia would increase
lactate production, we observed only a modest increase at the latest time point in our
experiment. Two interesting observations did come from this experiment. First, in all
cases, treating the cells with low glucose simultaneous with low oxygen, radically
decreased the production of lactate, indicating that indeed glycolysis was not possible
without sufficient availability of glucose. Thus it is likely that the cells are more reliant
on oxygen for energy production and might become more hypoxic at a given
concentration of oxygen or at an earlier time after switching to low oxygen conditions. A
second interesting result was found with cells that were subjected to the combination of
thapsigargin and hypoxia. As expected, in this case there was no effect of the UPR on
lactate production. Based on this hypothesis, we would not have expected a synergy with
thapsigargin and hypoxia on VEGF production. However, inspection of VEGF
transcription rates with this combination of stresses reveal higher levels of VEGF
induction than with either stress alone (data not shown).
Discussion
A limiting microenvironment can activate cellular stress pathways like the UPR
and HIF signaling when nutrients and oxygen levels are suboptimal. These pathways
synergize to positively regulate proangiogenic factors, which stimulate growth of new
blood vessels toward the affected cells to restore homeostasis. Our tissue culture studies
revealed that the UPR and HIF signaling pathways induce VEGF expression to a greater
extent than each of the stress pathways alone. In the case of a rapidly proliferating tumor
mass, there should be a subpopulation of tumor cells that activate both stress pathways
together, which would result in greater secretion of VEGF as compared to tumor cells
that have only one pathway activated. The mechanism for this synergy in the case of a
pharmacological UPR activator like thapsigargin is unknown, although in the case of low
glucose our data allows us to speculate. Tumor cells have an altered metabolism that
enables them to produce significant amounts of ATP from glycolysis rather than
oxidative phosphorylation. By decreasing the oxygen supply to a cell we would expect to
see a further increase in its glycolytic potential. The synergistic induction in VEGF
expression when observed when both stresses were present together led us to speculate
that when glucose was limited the cell would be forced to rely more on oxidative
phosphorylation, which might further decrease cellular oxygen levels and result in more
hypoxic conditions in the cell for a given concentration of oxygen. Indeed, we found that
the levels of glucose in our “low glucose” conditions was not sufficient to support
glycolysis as a means of energy production. This would imply that the cells were either
producing less ATP or producing it via oxidative phosphorylation. To distinguish
between these possiblities, it would be necessary to measure cellular ATP levels or
oxygen consumption by the mitochondria, as this is where oxidative phosphorylation
takes place. If the synergy on VEGF transcription that we observed with low glucose and
hypoxia was due to increasing the intracellular level of hypoxia, we would not have
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expected to see a synergy when thapsigargin was used to activate the UPR with hypoxia,
since this did not reduce lactate production. However, we also found that VEGF mRNA
levels were significantly higher when these two activators were combined. Thus, there
must be another mechanism for synergy between these responses. It is formally possible
that in this case ATF4 still binds to the VEGF promoter to increase transcription.
Experiments with this combination of stresses will be conducted in the ATF4 deficient
cells. Importantly, these data have been obtained with a single line and must be
reproduced in another line before we can draw conclusions. However, if they hold, these
results have very important implications in tumor angiogenesis, as they might argue
against a need to target the UPR pathway to inhibit VEGF production in cells where both
stress pathways are activated due to both limited oxygen and glucose.
The importance of HIF1 in regulating VEGF expression is well documented in
the literature. To the best of our knowledge, HIF1 has not been shown to be regulated
by UPR activation. Experiments designed to understand the mechanism by which the
UPR increases the activity of this factor in regulating VEGF and at least one other HIF
target, BNIP3 expression when both stresses are applied together revealed an interesting
finding. We found that these dual conditions appeared to modestly increase HIF1
binding to the human VEGF promoter, although importantly the experiment was not
conducted in a way to measure quantitative increases in binding. Interestingly, we did
observe a modest induction (~2 fold) in the HIF1 transcription rate (hnRNA) with the
combination of both stresses together, but this was not sufficient to noticeably increase
VEGF mRNA or protein levels. Thus it is possible that at later time points we would
begin to see an increase in VEGF transcripts, but within the time frame of our
experiments, this was not the cause of increased HIF1 binding to the promoter. On
preliminary inspection of the HIF1 promoter we were able to identify potential binding
sites for XBP1(S), ATF4 and NFkB, which are activated downstream of the UPR, but
further experiments will be needed to determine the significance of this slight increase in
HIF hnRNA, particularly given the fact that we did not see this increase with UPR
activation alone . It is possible to speculate that the UPR has the ability to modify the
chromatin structure of the VEGF promoter at this site, or enhance the transcriptional
machinery or HIF1 co-factors, like p300/CBP, to facilitate HIF1 binding to the VEGF
promoter and thus indirectly contributing to VEGF expression. Further studies will be
required to determine if any of these changes occurs. Lastly, and perhaps more likely in
the case when low glucose is used to activate the UPR, it is conceivable that cells become
hypoxic at an earlier time point, which might result in the stabilization of HIF1 even
before ATF4 is synthesized. Although the two sites are not particularly close on the
linear sequence of the gene, it is possible that the binding of the HIF1 complex to its
site on the promoter precludes the binding of ATF4 to its site. The experiments where
thapsigargin and hypoxia are used together might shed light on this possibility.
From these experiments one thing we can definitely conclude is that the interplay
between these two pathways in regulating VEGF expression is complex and further
experiments will be required to determine the exact mechanism of how they synergize
with one another. Our future experiments will elucidate the importance of ATF4 in
regulating tumor angiogenesis in orthotopic xenograft studies.
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Materials and Methods
Cell culture and stress induction
SKNASluc and NB1691luc human neuroblastoma cell line stably expressing
luciferase were maintained in RPMI 1640 supplemented with 10% fetal bovine serum, 2
mM glutamine and 1% antibiotic-antimycotic at 37ºC in a 5% CO2 incubator. Cells were
plated and left untreated (NT) or treated with thapsigargin (Tg, 1µM), media containing 1
mM glucose (Low Glu) (RPMI cat. no.11879-GIBCO), or cultured in a hypoxia chamber
containing 1% O2 for the indicated periods of time.
mRNA and hnRNA quantification by qRT-PCR
Total RNA was extracted using the RNeasy Qiagen mini-prep kit according to the
manufacturer’s protocol. RNA samples were subjected to reverse transcription using
High Capacity cDNA synthesis kit from ABI Life technologies. The cDNA was diluted
and Real-time PCR reactions were done in duplicate using a SyBr Green PCR Master
Mix kit. Amplification of the corresponding genes was achieved using specific primers
and measured continuously using an ABI 7900 HTI Detection System. Where indicated,
VEGF hnRNA was measured using qRT-PCR primers across exon 1 and intron 1, for the
human gene. The signal obtained for measuring both, mRNA and hnRNA, was
compared relative to GAPDH internal control. The value for untreated cells was set to 1
and the value for the various treatments was presented as a fraction of this number. The
primers used in this study were as follows: VEGFhnRNA Fwd
5’GCTGTCTTGGGTGCATTGGAG3’Rev 5’CCATGGACCCGCGTGG5’
VEGFmRNA Fwd 5’GTAGCTCGGAGGTCGTGGCGC3’ Rev
5’GCGAGAACAGCCCAGAAGTTGGACGA3’
Gadd34mRNA Fwd 5’GCCAGAAAGGTGCGCTTCTC3’
Rev 5’CTCAGCTCCTCCTGGGCC3’
BNIP3mRNA Fwd 5’TTAAACACCCGAAGCGCACGG3’ Rev
5’GACTCCAGTTCTTCATCAAAAGGT3’
HIFhnRNA Fwd5’GTGCCCTTTTTAGGTGATTTG3’ Rev
5’GTGCATTTTACCTGAGTTAATCCC 3'
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) analysis was performed using a ChIP kit
(Millipore) according to the manufacturer’s instructions. Briefly, cells were incubated for
the indicated times with or without different stress inducers. Formaldehyde was then
added (final concentration, 1%), and cells were incubated for 10 minutes at room
temperature to stabilize DNA-protein interactions. Cross-linking was stopped by the
addition of glycine (final concentration, 0.125M). Cell extracts were sonicated with a
Branson Sonifier 250 (VWR) for 5 bursts at 10 seconds each at 20% power output to
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shear DNA to 1kb or less. Extracts from 107 cells were incubated overnight with
antibodies against ATF4 generously provided by Dr. David Ron (University of
Cambridge, U.K.), rabbit anti-XBP-1(S) polyclonal antiserum (Santa Cruz Biotechnology
sc-7160X), anti-HIF1α (Abcam) or rabbit anti-BiP polyclonal antiserum, which served as
a negative control. Two percent of the extract volume was removed before
immunoprecipitation and served as input control. DNA fragments from
immunoprecipitated complexes and input controls were released by heating at 65ºC
overnight and purified using the PCR purification kit (QIAquick, Qiagen) according to
the manufacturer’s protocol. Purified immunoprecipitated DNA and input DNA were
then analyzed by PCR. The primers used to amplify the regions on the human VEGF
promoter are as follows:
“HIF” binding site Fwd 5’GGCTTGGGGAGATTGCTCTACTTCC3’ Rev
5’GCGAGAACAGCCCAGAAGTTGGACGA3’
“ATF4” binding site Fwd 5’GGTCGGGCCTCCGAAACCATGAACT3’
Rev 5’GCAGCGGCAACGCAAGCCCAGC3’
“XBP-1(S)” binding site Fwd 5’GGTGGGAGCTCTGGGCAGCTGG3’
Rev 5’CCAGGGGAGAAGAATTTGGCACCAA3’
Western blotting
For Western blotting cells were lysed in Nonidet P-40 lysing buffer (50 mM TrisHCl (pH 7.5), 150 mM NaCl, 0.5% Nonidet P-40, and 0.5% deoxycholic acid) for 30
minutes on ice. The proteins were electrophoresed under reducing conditions, transferred
to a PVDF membrane and probed with the indicated primary antibodies: Rabbit
anti-XBP-1(S), rabbit anti-ATF4, goat anti-Hsc70, and goat anti-Lamin B1 were
purchased from Santa Cruz Biotechnology and mouse anti-HIF1α from BD Biosciences.
Blots were incubated with the appropriate HRP-conjugated secondary antibody, and
proteins were visualized using the Pierce enhanced chemiluminescent substrate (Thermo
Scientific).
Vascular endothelial growth factor ELISA
The quantikine human VEGF ELISA kit (R&D Systems) was used to measure the
VEGF levels in treated and untreated culture supernatants. VEGF secreted in the media
was determined based on a standard curve and was expressed in pg/1x106 cells.
Generation of dox-inducible ATF4 shRNA in the SKNASluc cell line
Two separate shRNA sequences targeting human ATF4, one specific for the
3’UTR of the gene and a second sequence that targets exon 4, were cloned into the
pSuperior-puro vector (Oligoengine), which expresses shRNA molecules from a
doxycycline-inducible H1 promoter. Both these sequences were validated previously
using transient siRNA knockdown experiments in the neuroblastoma lines. Two separate
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vectors; one containing the tetracycline repressor and the other encoding the ATF4
shRNAs were stably transfected in the SKNASluc cell line. Blasticidin (3g/ml media)
and Puromycin (1g/ml media) were used to select for clones stably expressing the tetrepressor and p-Superior vectors respectively. After obtaining antibiotic-resistant double
transfectants, a number of individual clones were picked using cloning cylinders and
screened for regulated knock-down of ATF4 expression. Cells were treated with or
without doxycycline for 24 or 48 hrs and then treated with thapsigargin for 16 hrs as
indicated, and the level of ATF4 expression was determined using Western blot analysis.
The ATF4 shRNA sequence used to clone in the pSuperior vector with BglII and Xho1
overhangs is as follows: Fwd
5’GATCCCCCCTTCTGACCACGTTGGATTTCAAGAGAATCCAACGTGGTCAGA
AGGTTTTTA3’ and Rev
5’TCGATAAAAACCTTCTGACCACGTTGGATTCTCTTGAAATCCAACGTGGTCA
GAAGGGGG3’
Lactate assay
The SKNASluc neuroblastoma cell lines were treated as indicated above. Posttreatment cells were harvested for Western blot analysis and media was collected to
measure lactate production. Media was deproteinized using a 10 kd spin column
(Biovision) following which the media was used to determine lactate amounts using a
Lactate Assay Kit (Biovision).
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CHAPTER 4. ROLE OF THE UPR-INDUCIBLE TRANSCRIPTION FACTOR
ATF4 IN REGULATING ANGIOGENESIS IN VIVO
Introduction
After acquiring genetic changes that result in a neoplastic phenotype, highly
proliferative cancer cells survive in a limiting environment that activates cytoprotective
stress pathways including the UPR, which has been documented in a number of tumor
types including breast, hepatocarcinoma, gastric cancer and gliomas in both patient
samples and xenograft studies.
The three signal transducers of the UPR: Ire1, PERK and ATF6 have reported to
play roles in regulating tumor angiogenesis in xenograft studies. To elucidate the role of
Ire1 in regulating tumor growth and angiogenesis in vivo, two separate studies engineered
U87 human glioma cells with either an Ire1 dominant negative mutant or a control empty
vector and then orthotopically implanted them in mice [42, 43]. In both studies, tumors
derived from cells expressing the Ire1-dominant negative mutant were significantly
smaller, less vascularized but more highly infiltrative as compared to their control
counterparts. Cells grown in hypoxic/anoxic conditions in tissue culture and in hypoxic
areas of the tumor activate a translational control program called the Integrated Stress
Response (ISR), which adapts cells to endoplasmic reticulum stress. Tumors derived
from K-ras transformed PERK-/- MEFs were much smaller and had decreased
microvessel density as compared to the tumors derived from PERK wild-type MEFs
when injected in the flank of the animals. The decreased angiogenic phenotype observed
in PERK-/- MEFs was analyzed by microarray and was attributed to down-regulation of
proangiogenic factor VCIP, an adhesion molecule required for capillary tube formation
[46].
Using microarray analysis in a human medulloblastoma line, we found that a
large number of proangiogenic factors including VEGF were up-regulated by
thapsigargin. Four proangiogenic factors, VEGF, FGF2, angiogenin and IL8 were further
analyzed using Real-time PCR. The up-regulation of these factors by ER stress was as
robust as, or even greater than, that achieved with hypoxia in several different cell lines
tested. We found that two UPR-regulated transcription factors, ATF4 and XBP-1(S)
bound directly to the VEGFA promoter in response to ER stress and contributed to its
transcription. In addition, activation of AMP kinase stabilized the VEGFA transcripts,
further contributing to VEGFA mRNA levels. At the same time our study was published
another group reported the importance of the UPR transcription factors, ATF4, XBP-1(S)
and ATF6 in regulating VEGF mRNA using different knockout MEFs.
An intact UPR is required for various aspects of tumor growth, proliferation and
angiogenesis. Targeting various components of the UPR is a promising strategy for
treatment of cancer. A recent study identified STF-083010, a novel small-molecule
inhibitor of Ire1 endonuclease activity but has no effect on its kinase activity. The
efficacy of this molecule was tested in a human model of multiple myeloma and was
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shown to decrease disease burden as compared to untreated controls [124]. Another study
identified a small molecule, guanabenz that disrupted the stress-induced
dephosphorylation of the α subunit of the translation initiation factor-eIF2 by direct
binding to the protein phosphatase 1 PPR15A/Gadd34. Treatment of stressed-cells with
this inhibitor enabled them to cope with the increased burden of unfolded proteins by
inhibiting production of new protein and thus restoring proteostasis during stressful
conditions [125]. Inhibiting critical components of the UPR is a promising strategy as
treatment options for several disease conditions. To assess the contribution of ATF4 in
regulating angiogenesis in vivo we will use an inducible knockdown system to inhibit
expression of this factor in a neuroblastoma tumor model.
Neuroblastoma is the most common solid childhood tumor of the peripheral
sympathetic nervous system and accounts for 7-10% of all pediatric cancers [126]. The
tumors arise typically in the adrenal medulla or paraspinal ganglia that can present as
lesions in the neck, chest, abdomen or pelvis. The clinical presentation of the disease is
highly variable and can range from a mass that can regress spontaneously, especially in
infants, to a primary tumor that can locally invade surrounding tissues or a distantly
disseminated disease observed in children of greater than one year of age. The common
genetic changes associated with neuroblastoma include N-Myc oncogene amplification
[127], loss of caspase-8 expression either through gene methylation or deletion [128],
near triploid karyotype [129] and deletion of short arm of chromosome 1 [130], these
changes have been correlated with the clinical prognosis of the disease. For example, a
near-triploidy change in the karyotype of the patient is associated with favorable outcome
whereas MYCN amplification or allelic loss at chromosome 1p is associated with more
aggressive tumors and poor prognosis. Studies by different groups have identified three
discrete sites that are deleted on chromosome 1p36 in neuroblastoma. These regions are
being mapped intensively to identify putative tumor suppressor genes that are deleted in
neuroblastoma patients. Based on the phenotypic and genetic features of the disease,
neuroblastoma is stratified as low, intermediate and high risk [131]. Low risk tumors are
localized, can be treated by surgery alone and the survival rate is >98%. Intermediate risk
neuroblastomas most often occur in infants and are characterized by a localized tumor
with regional lymph node invasion and metastases to bone marrow and bone. The
treatment approach is moderate-intensity chemotherapy and surgery that results in a
90-95% survival rate. High-risk tumors predominantly occur in children older than one
year of age and are characterized by metastases to bone marrow and bone. These patients
are treated with intensive multimodal therapy that includes dose-intensive chemotherapy,
surgery, radiotherapy to primary tumor and resistant metastatic sites, myeloablative
chemotherapy and immunotherapy. Despite aggressive treatment options, patients older
than one year and having advanced stage of the disease have a poor survival rate. Only
40% of neuroblastoma patients that after the age of 4 years survive for 5 years, making it
necessary to develop more effective and innovative therapy for treatment of malignant
neuroblastoma.
Neuroblastoma is a highly vascularized solid tumor that depends on the tumor
vasculature for growth, invasion and metastases. Although the biological mechanisms
regulating the clinical heterogeneity of neuroblastoma is not completely understood,
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several recent reports have implicated the importance of using anti-angiogenic therapy as
a successful treatment strategy for this pediatric cancer. There are three kinds of
angiogenic inhibitors described: direct, indirect and mixed inhibitors. Direct inhibitors
like endostatin, angiostatin and thrombospondin target microvascular endothelial cells
that are required for the proliferation, growth and formation of new blood vessels.
Indirect inhibitors are agents that are used to block the activity of growth factors like
VEGF or PDGF that are produced by tumor cells. Lastly, mixed inhibitors are
multipotent tyrosine kinase inhibitors or interferon-α that affect both tumor cells and
endothelial cells. The Food and Drug Administration (FDA) have approved several antiangiogenic agents for use in clinical trials including bevacizumab (Avastin), a
monoclonal antibody that binds to VEGFA and blocks the subsequent activation of its
receptor signaling [132]. This agent was shown to slow tumor growth and extend the life
of patients with cancers like colorectal, non-small cell lung cancer and colon cancer.
Bevacizumab has been used in several xenograft studies to assess its efficacy as treatment
strategy for neuroblastoma. One study reported that established orthotopic neuroblastoma
xenografts treated with this drug, altered the physiology of the tumor blood vessels,
which improved delivery and efficacy of chemotherapeutic agents to the tumor [133].
Another study reported that SKNAS, IMR32 and SH-SY5Y xenografts treated with
bevacizumab were much smaller than their untreated counterparts due to reduced
angiogenesis [134]. A third study assessed the efficacy of anti-VEGF therapy in
disseminated disease using the NB1691 cell line. Although they observed a decrease in
tumor burden and prolonged survival of tumor-bearing mice treated with bevacizumab,
there was an increase in basic fibroblast growth factor and VEGF expression most likely
due to inhibition of VEGF signaling [135]. Taken together, these results emphasize that
VEGF blockade in combination with chemotherapy can be an effective strategy to treat
neuroblastoma patients.
Validating our tissue culture results in an animal model is a critical step toward
delineating the contribution of the UPR-inducible transcription factor ATF4 in mediating
angiogenesis in vivo and determining whether the UPR might represent a druggable target
for the treatment of neuroblastoma. Because the PERK pathway, which is responsible for
ATF4 induction during the UPR, has been shown to be required for growth of K-Ras
transformed MEFs [46], we have chosen to use a regulated shRNA system for knocking
down expression of ATF4 in human neuroblastoma cell lines. This will give us the
flexibility to turn off expression of this factor during various stages of tumor
development to allow the evaluation of target inhibition on tumor initiation, maintenance
and metastases.
Results
Neuroblastoma tumors show evidence of UPR activation
A large number of primary tumor types from St. Jude patients have been adapted
for xenograft studies and were available for our studies. However, before choosing a
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model system for these studies, we wished to identify one that might have relevance to a
human cancer. Using an affinity purified, anti-CHOP polyclonal antiserum for
immunohistochemistry staining, we found that multiple pediatric tumor types expressed
this UPR-induced transcription factor. We chose neuroblastoma as our model system,
since a significant number of the pediatric tumor samples were positive for UPR
activation (Figure 4-1A), there are numerous well-established xenograft lines, and genetic
mouse models are available. In situ hybridization analyses of tumor sections obtained
from TH-MYCN hemizygous mice, a transgenic mouse model of neuroblastoma [136],
revealed up-regulation of BiP mRNA expression, a molecular chaperone that is a UPR
target, in tumor cells (Figure 4-1B), demonstrating evidence of UPR activation in the
mouse model similar to that observed in the patient samples. Together, these data provide
us with evidence that neuroblastoma is a good model system to study the role of UPR
activation in regulating angiogenesis.
Neuroblastoma cell lines induce VEGF secretion on UPR activation
A large number of patient neuroblastoma cell lines have been established at St.
Jude for use in xenograft studies. These represent the variety of distinct molecular
signatures that are observed in patient tumors, including deletion or inactivation of
caspase-8, a cysteine protease regulated in both a death receptor-dependent and
independent manner during apoptosis, and/or amplification of the MYCN oncogene [137].
We obtained 22 different neuroblastoma (NB) cell lines from Dr. Jill Lahti and Dr
Andrew Davidoff at St. Jude and analyzed them by ELISA for their ability to induce
VEGF secretion upon UPR activation. The lines were treated with or without
thapsigargin for 24 hrs and culture supernatants were collected and analyzed. We found
that VEGF secretion was significantly induced in all cell lines after treatment with
thapsigargin, however, the fold induction was quite variable (Figure 4-2). Some lines,
such as NB14 and NB16, have a very high basal level of VEGF secretion, making them
poor candidates for our studies even though VEGF production was further increased with
ER stress. Whereas, several others, including SKNAS, NB7 and NB15 lines have a very
low basal level of VEGF secretion and potently induce VEGF on UPR activation making
them particularly good candidates for determining the role of the UPR in regulating
VEGF expression. The VEGF secretion data was further categorized based on two known
genetic features associated with this cancer (Figure 4-3). Cell lines were first grouped
into three categories for MYCN protein expression; high, intermediate and low. We
observed no correlation in any of the groups for either basal levels of VEGF expression
or the fold increase in VEGF secretion after UPR activation. Next, the cell lines were
subgrouped according to caspase-8 protein expression. Once again, we found cell lines
with both high and low basal level of VEGF expression that showed varying levels of
induction. Thus, UPR-induced VEGF secretion appeared to be independent of both the
MYCN protein levels and caspase-8 status.
Based on these analyses, we decided to choose lines the SKNASluc and
NB1691luc cell lines to perform our animal xenograft experiments, as these lines were
potent inducers of VEGF on UPR activation and both lines have been engineered to
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A.

B.

Figure 4-1. UPR activation in neuroblastoma tumors. (A) Slides from the tumor
tissue arrays were stained with rabbit anti-CHOP antiserum. Portions of two slides are
shown at low magnification at the left. A single tumor sample from each slide is
enlarged. The top panel is a sample from a ganglioneuroblastoma. CHOP expression is
detected in the large ganglian-like cells and in the smaller more poorly differentiated
neuroblastomas cells that form this tumor. (B) Tumor sections were obtained from a
genetic mouse model of neuroblastoma (TH-MYCN). The left panel shows Hematoxylin
and Eosin staining; the darker stained area is the tumor sample with highly proliferative
cells. The right panel shows expression levels of BiP mRNA by in situ hybridization.
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Figure 4-2. UPR activation potently induces VEGF secretion in neuroblastoma cell lines. 22 different Neuroblastoma
cell lines were either left untreated or treated with thapsigargin, a UPR inducer, for 24 hours. Media was collected and VEGF
secretion was measured using ELISA assay. Results are represented as amount of VEGF secreted in pg/ml per 1 million cells.
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A.

B.

Figure 4-3. UPR-induced VEGF secretion in neuroblastoma lines is independent of MYCN amplification and
caspase-8 protein. Neuroblastoma lines were either left untreated or treated with thapsigargin for 24 hours. Media was
collected and VEGF secretion was analyzed using ELISA. The NB lines were categorized based on (A) MYCN amplificationhigh, moderate or low and (B) caspase-8- presence or absence.
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express luciferase, which makes it possible to do live cell imaging of tumor growth in
either orthotopic and flank xenograft studies. In addition, these two lines were selected
based on their genotype; SKNAS expresses caspase-8 protein, whereas NB1691 does not,
and the SKNAS cell line has low MYCN protein expression, whereas NB1691 has high
MYCN expression. Thus, we have a representative cell line from each of these major
categories, which should make our studies more clinically relevant.
Engineering ATF4 inducible stable knockdown neuroblastoma lines
Since previous studies have shown that full activation of the UPR, including the
PERK pathway that regulates ATF4 expression, is critical for tumor growth and survival,
we will use an inducible system to knockdown ATF4 before and after the tumor has been
established in animal. This design is also critical for determining potential feasibility of
manipulating the PERK-ATF4 branch of the UPR to treating existing patient tumors.
Two separate shRNA sequences targeting human ATF4, one specific for the 3’UTR of
the gene and a second sequence that targets exon 4, were cloned into the pSuperior-puro
vector (Oligoengine), which expresses shRNA molecules from a doxycycline-inducible
H1 promoter. Both these sequences were validated previously using transient siRNA
knockdown experiments in the neuroblastoma lines. Two separate vectors; one
containing the tetracycline repressor and the other encoding the ATF4 shRNAs were
stably transfected in the SKNAS cell line. After obtaining antibiotic-resistant double
transfectants, a number of individual clones were obtained and screened for regulated
knock-down of ATF4 expression. Cells were treated without or with doxycycline for 24
or 48 hrs and then treated with thapsigargin for 16 hours as indicated, and the level of
ATF4 expression was determined using Western blot analysis (data not shown). Two
representative clones for a single ATF4shRNA sequence are shown here. While both
clones showed robust induction of ATF4 in response to thapsigargin, pretreatment with
dox for 24 or 48 hour was sufficient to significantly block its expression in response to
thapsigargin (Figure 4-4A). These two clones were further analyzed for the effects of
shRNA expression on the UPR-induced VEGF transcription rate using Real-time PCR
(Figure 4-4B). VEGF hnRNA levels, an indication of transcription rate, were
significantly reduced in response to both thapsigargin and low glucose in both of the two
SKNAS-ATF4 shRNA clones after dox pretreatment as compared to the control lines,
strongly supporting the role for ATF4 being a major regulator of UPR-induced VEGF
expression. As a control, Gadd34 up-regulation, a well-characterized ATF4 target, was
inhibited in the shRNA-expressing lines and induced in the control lines on UPR
activation (Figure 4-4C).
Cell cycle analysis of SKNASluc ATF4 shRNA lines
Before initiating xenograft studies, we wish to determine if the genetic
manipulations and clonal selection have any gross effects on cell growth. To determine
this, we will perform two analyses. The first was to assess cell growth of these two
clones before and after dox treatment compared to the control line. We found that the
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Figure 4-4. SKNASluc lines with Dox-inducible expression of ATF4- an
important factor regulating VEGF transcription rate. (A) Western blot analysis of
SKNAS-ATF4 shRNA clones were either left untreated or treated with Dox for 24hours
or 48hours. The cells were further treated with thapsigargin for 16hours to induce the
UPR and ATF4 levels were determined. Real-time PCR analysis of (B) VEGF hnRNA
and (C) Gadd34, an ATF4 downstream target, was measured in the control and ATF4shRNA lines in untreated samples or samples treated with the UPR inducers thapsigargin
(Tg) or media lacking glucose (Lglu) after 48 hours of pretreatment with dox.
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two clones expressing ATF4shRNA grew at a similar rate with the control SKNASluc
cell line in the absence of Doxycycline (Figure 4-5A). In the presence of Doxycycline
(Figure 4-5B) the control parental line grew slightly faster than the lines having stable
expression of ATF4shRNA. We are in the process of cloning the negative control
shRNA (Renilla luciferase) in the parental SKNASluc line, which will be used in future
orthotopic xenograft studies. We expect that after obtaining stable Ren luc-shRNA clones
they would also have the same proliferation rate as our ATF4shRNA clones. We are
currently analyzing cell cycle distribution of the two clones and the control line before
and after induction of shRNA expression with dox.
Future Experiments/Discussion
Orthotopic xenograft experiments to analyze effects on tumor size and
vascularization after knocking down ATF4
The next critical aspect of characterizing these clones was to insure that both
would still produce tumors in nude mice. It was possible that in our genetic
manipulations, we would have isolated clones that no longer were strongly tumorogenic.
Alternatively, it was possible that the shRNA would be somewhat leaking even in the
absence of dox administration and interfere with tumor growth. To test for these
possiblities, we performed flank injections in three SCID mice each with either the
control SKNASluc line or the two clones that inducibly expressed ATF4 shRNA.
Although in our initial experiment the control line grew up slightly faster, all of the
clones resulted in tumor growth within 3-4 weeks. The tumors resulting from the two
ATF4 shRNA clones were visualized using the Xenogen imaging machine as these lines
have stable luciferase expression (Figure 4-6). The animals were sacrificed and the
tumors were either flash frozen or formalin-fixed and paraffin embedded for further
analysis. This will include analyzing the tumor sections for UPR target genes like ATF4
and XBP-1. We will also perform IHC analysis to visualize HIF staining in the tumors.
Now that we have preliminary data showing that the clones expressing inducible
ATF4 shRNA are able to form well-vascularized tumors in nude mice, we will next
perform orthotopic xenograft studies, in order to establish tumors from the conditional
knockdown cell lines in a clinically relevant microenvironment. The dox-inducible
neuroblastoma cell lines will be injected orthotopically in the retroperitoneal cavity in
SCID mice.
The animals receiving retroperitoneal injections of the genetically manipulated
SKNASluc cells will be randomized into 2 main groups, i.e., those with shRNA specific
for ATF4 and those with shRNA specific for Renilla luciferase as negative control. Prior
to knocking down ATF4 expression, we will confirm its presence in tumors that reach a
size of ~100 mm3 by sacrificing two animals in each group, harvesting the tumor and
performing western blot analysis to detect ATF4 expression and its downstream targets.
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Figure 4-5. Cell proliferation rate in the SKNASluc control and ATF4shRNA
clones. The SKNASluc cell line and two clones with stable expression of ATF4shRNA
were either (A) untreated or (B) treated with Doxycycline for 2 or 3 days as indicated in
the figure. Post-treatment the cells were trypsinized and counted.

Figure 4-6. Inducible ATF4shRNA clones in the SKNASluc cell line form tumors
when injected in the flank of SCID mice. SKNASluc cells expressing Dox-inducible
ATF4shRNA were injected into the flank of SCID mice at 1x107 cells per site. Two
clones expressing the same shRNA targeting ATF4 were tested with 3 animals per group.
28 days later tumor growth was visualized by injecting mice with luciferase substrate Dluciferin and was imaged with a Xenogen CCD camera.
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Once expression is confirmed, each group will be further divided into 4 subgroups
(8 animals/group), one group will receive doxycycline 7 days after surgery, as the
animals need to recover from the invasive procedure. The second group will receive
doxycycline when tumors reach an average size of at least 100 mm3 and the third group
will receive doxycycline at a late stage in tumor development when the average size is
about 250 mm3. The fourth group will be time-matched animals expressing these two
clones without receiving any dox. In the former case, animals will receive doxycycline
hyclate at a concentration of 25 mg/kg per day by oral gavage, four times a week for the
duration of the study. This will induce the knockdown of ATF4 in the SKNAS ATF4
shRNA group but should have no effect on ATF4 expression in the control shRNA
group. Time-course experiments with doxycycline will be performed to determine the
number of days required for administration of the drug to obtain efficient knockdown of
ATF4 and to assess the optimum time at which tumors will be harvested after
doxycycline administration. In this way we can determine the short term and long term
effects of knocking down ATF4 on tumor angiogenesis, as well as to assess
vascularization in the various tumor samples prior to administering doxycycline. The
animals in the control group (SKNAS Ren-luc negative control and receiving
doxycycline) will enable us to assess the effects, if any, doxycycline will have on the
general health of the animals. Once the tumors are established, the animals will be
monitored twice a week using the Xenogen luminometer, to assess tumor size at the
implantation site. Animals in all groups will be regularly monitored for signs of weight
loss and neurological symptoms. In our efforts to determine the effects of knocking down
the UPR-inducible transcription factor, ATF4, on tumor vascularization, we will perform
a combination of histological, vascular function and phenotype analysis on treated and
untreated tumors. We will first examine the effect of knocking down ATF4 on
microvessel density, pericyte coverage and tumor oxygenation status using the methods
outlined below. In addition to formalin-fixed tissue for in situ hybridization and
immunohistochemistry analyses, snap frozen tumor samples will be obtained to assess the
knockdown efficiency in the SKNAS ATF4 shRNA group and determine the extent of
ATF4 expression in the control groups.
Tumor endothelial cell staining: Formalin fixed, paraffin embedded tumors from
each group of animals will be obtained. 4µm thick sections will be analyzed by
immunohistochemistry for CD34, an endothelial cell marker and α-smooth muscle actin
(αSMA), a pericyte marker, as described previously. Four independent fields will be
analyzed using a light microscope. Positive staining will be quantified using Image J
software and will be reported as the mean number of positive pixels/tumor section. In situ
hybridization will also be performed to analyze mRNA levels of UPR target genes like
CHOP (an ATF4 target), BiP and ERdj3. We will also analyze activation of the HIF
pathway by probing for BNIP3 mRNA levels, a downstream target for HIF1 acivity.
RNA and protein analysis: RNA will be extracted from tumors expressing
ATF4shRNA and Renilla luciferase-shRNA. Real time PCR analysis will be performed
to determine expression of VEGF. We will also determine expression of other
proangiogenic factors like FGF2, IL8 and angiogenin. If ATF4 proves to be an important
regulator of VEGF from our in vitro experiments, then we will check if inhibiting VEGF
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in vivo has any effect on expression of the other proangiogenic genes important for
angiogenesis. In addition to analyzing expression levels of the proangiogenic factors, we
will perform Real-time PCR to determine levels of CHOP, a direct target of ATF4 and
ERdj3, an off-target control. We expect CHOP expression to be down-regulated in the
ATF4shRNA tumors as compared to tumors expressing Renilla luciferase shRNA.
ERdj3 expression levels should be similar in the tumors expressing targeted shRNA and
negative control shRNA. We will also perform Western blot analyses to determine
protein expression of ATF4 in knockdown and control tumors. In a similar manner
described for the in situ hybridization, we will also measure BNIP3 mRNA levels in
tumor tissue derived from control and ATF4 shRNA samples. Since both pathways, the
UPR and HIF, are simultaneously activated in tumors we will determine if knocking
down ATF4 expression has any effect on the HIF pathway.
Tumor oxygenation and intratumoral hypoxia: In a separate group of animals we
will examine the effects of inhibiting angiogenesis, by knocking down a UPR
transcription factor, on the oxygenation status of tumors. . We will determine tumor
oxygenation using a pO2 monitor. This apparatus measures oxygen based on the principle
of oxygen quenching of fluorescence using a small optical sensor for monitoring rapid
temporal oxygen changes in a given tissue micro region. We hypothesize that tumors
expressing ATF4 shRNA may have transient vessel normalization and increased oxygen
delivery to the tumor compared to control tumors. We would expect to observe a
transient increase in the pO2 in the ATF4 shRNA tumors as compared to control tumors.
Finally, to determine intratumoral hypoxia, mice will be injected i.p. with Hypoxyprobe1 (Chemicon International) 90 min prior to sacrifice. Tumors will be excised, fixed in
formalin and embedded in paraffin. Tumor sections will then be stained using the
Hypoxyprobe-1 Plus kit. Hypoxia (HIF) positive staining will be quantified using the
Image J software as described previously. Because tumor hypoxia can be affected by
tumor volume, size-matched tumors will be used for comparison. In a similar manner
described above, we anticipate decreased intratumoral hypoxia staining in the ATF4
shRNA tumors as compared to control tumors.
Functional analyses of the tumor vasculature
If experiments described above suggest that knocking down ATF4 in established
tumors inhibits tumor angiogenesis we will proceed to perform detailed functional
analyses of the tumor vasculature.
Evans Blue dye assay: VEGF is known to be a potent proangiogenic factor and
increases vessel permeability. To examine vessel permeability we will inject 100 µl of 2
% Evan’s dye via tail vein in the ATF4 shRNA and control group that will be allowed to
circulate for 20 min. Animals will be sacrificed and tumors will be excised and placed in
formamide for 72 hours to extract the dye. Levels of dye in the extract will be quantified
(µg/mg) using a spectrophotometer at 620 nm.
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Contrast Enhanced Ultrasonography: As a measure of functional tumor perfusion
we will perform contrast enhanced ultrasonography. Briefly, we will inject Optison
ultrasound contrast agent (Amersham Health, Inc.), which is a suspension of human
serum albumin microspheres encapsulating octafluoropropane gas. The mean
microsphere size ranges from 2-4.5 µm and particles remain in the intravascular space. A
region of interest will be drawn within the ultrasound to encompass the entire tumor,
which will then be analyzed for precontrast baseline signal intensity, change in signal
intensity from baseline to initial peak (in dB) and rate of signal intensity increase (in
dB/s). Using this imaging modality we can evaluate intratumoral perfusion by assessing
the two variables described above, the change in contrast enhancement and the rate of
this change. We expect ATF4 shRNA tumors to have improved tumor perfusion and
consequently these two variables will be much greater than those of the control tumors.
Finally, we can confirm the functional consequence of the improved tumor perfusion by
showing a decrease in the intratumoral hypoxia as described above.
Materials and Methods
Cell culture and stress induction
SKNASluc human neuroblastoma cell line stably expressing luciferase were
maintained in RPMI 1640 supplemented with 10 % fetal bovine serum, 2 mM glutamine
and 1 % antibiotic-antimycotic at 37ºC in a 5 % CO2 incubator. Cells were plated and left
untreated (NT) or treated with thapsigargin (Tg, 1 µM), media containing 1 mM glucose
(Low Glu) (RPMI cat. no.11879-GIBCO), or cultured in a hypoxia chamber containing
1% O2 for the indicated periods of time.
mRNA and hnRNA quantification by qRT-PCR
Total RNA was extracted using the RNeasy Qiagen mini-prep kit according to the
manufacturer’s protocol. RNA samples were subjected to reverse transcription using
High Capacity cDNA synthesis kit from ABI Life technologies. The cDNA was diluted
and Real-time PCR reactions were done in duplicate using a SyBr Green PCR Master
Mix kit. Amplification of the corresponding genes was achieved using specific primers
and measured continuously using an ABI 7900 HTI Detection System. Where indicated,
VEGF hnRNA was measured using qRT-PCR primers across intron 1 and exon 2, for the
human gene. The signal obtained for measuring both, mRNA and hnRNA, was
compared relative to GAPDH internal control. The value for untreated cells was set to 1
and the value for the various treatments was presented as a fraction of this number.
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Western blotting
For Western blotting cells were lysed in Nonidet P-40 lysing buffer (50 mM TrisHCl (pH 7.5), 150 mM NaCl, 0.5 % Nonidet P-40, and 0.5 % deoxycholic acid) for 30
minutes on ice. The proteins were electrophoresed under reducing conditions, transferred
to a PVDF membrane and probed with the indicated primary antibodies: Rabbit antiXBP-1(S), rabbit anti-ATF4, goat anti-Hsc70, and goat anti-Lamin B1 were purchased
from Santa Cruz Biotechnology and mouse anti-HIF1α from BD Biosciences. Blots were
incubated with the appropriate HRP-conjugated secondary antibody, and proteins were
visualized using the Pierce enhanced chemiluminescent substrate (Thermo Scientific).
Vascular endothelial growth factor ELISA
The quantikine human VEGF ELISA kit (R&D Systems) was used to measure the
VEGF levels in treated and untreated culture supernatants. VEGF secreted in the media
was determined based on a standard curve and was expressed in pg/1x106 cells.
Generation of dox-inducible ATF4 shRNA in the SKNASluc cell line
Two separate shRNA sequences targeting human ATF4, one specific for the
3’UTR of the gene and a second sequence that targets exon 4, were cloned into the
pSuperior-puro vector (Oligoengine), which expresses shRNA molecules from a
doxycycline-inducible H1 promoter. Both these sequences were validated previously
using transient siRNA knockdown experiments in the neuroblastoma lines. Two separate
vectors; one containing the tetracycline repressor and the other encoding the ATF4
shRNAs were stably transfected in the SKNAS cell line. Blasticidin (3 g/ml media) and
Puromycin (1g/ml media) were used to select for clones stably expressing the tetrepressor and p-Superior vectors respectively. After obtaining antibiotic-resistant double
transfectants, a number of individual clones were picked using cloning cylinders and
screened for regulated knock-down of ATF4 expression. Cells were treated with or
without doxycycline for 24 or 48 hrs and then treated with thapsigargin for 16 hrs as
indicated, and the level of ATF4 expression was determined using Western blot analysis.
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CHAPTER 5.

DISCUSSION

In normal tissues, an appropriate balance between proangiogenic and
antiangiogenic factors is required to regulate the formation and maintenance of the
vasculature. A functional network of blood vessels fuels normal tissues and organs with
nutrients, growth factors, signaling molecules and oxygen. The growth of blood vessels
or angiogenesis is essential from the early stages of embryonic development, organ
morphogenesis and throughout adult life. During adulthood, blood vessels are mostly
quiescent, except in the cycling ovary, during wound healing and in the placenta during
pregnancy. Its importance has also been implicated in several disease conditions, like
ischemia, macular degeneration and cancer. Over the past two decades, genetic studies in
different animal models including mice, zebrafish and tadpoles have provided insights
into the molecular mechanisms and signaling molecules involved in the regulation and
growth of new blood vessels. VEGF is the most potent proangiogenic factor required for
angiogenesis. Other proangiogenic factors like bFGF, and cytokines like IL8 and IL6 also
contribute to stimulating the development of new blood vessels. Proangiogenic factors
like PDGF and angiopoeitin-1 play important roles in recruitment of supporting mural
cells around endothelial tubes. Angiogenesis is a complex process that requires a finetuned balance of several stimulatory and inhibitory signals, chemokines, growth factors,
oxygen sensors and endogenous inhibitors. The remarkable ability of endothelial cells to
divide and proliferate in response to physiological stimuli like hypoxia, which leads to
subsequent activation of the HIF pathway, has been the focus of numerous studies. In
addition, recent data from several labs, including ours, have implicated the UPR in the
production of proangiogenic factors, which suggested that it might also contribute to
blood vessel formation.
UPR Activation Regulates Angiogenesis in Normal Physiological Processes
The UPR is constitutively activated in certain normal tissues and organs like the
pancreas and muscle that have a high metabolic rate or secrete large amount of proteins.
It is well established that this cytoprotective response increases ER chaperones, folding
enzymes and ERAD machinery to enable the ER to cope with increased metabolic
demands. However, in the past several years increasing evidence obtained primarily from
experiments with cultured cells, suggests that activation of the UPR might also play an
important role as a global regulator of angiogenesis by preferentially increasing
expression of proangiogenic factors and down-regulating antiangiogenic factors [49].
Data to support a role in normal angiogenesis came from a recent study where the Ire1
gene was disrupted. Ire1 is an up-stream UPR transducer that is conserved from yeast to
humans and plays a critical role in regulating membrane biosynthesis, molecular
chaperones, components of the ER degradation machinery, and even cell death [19]. Ire1
is expressed throughout mouse embryogenesis and adult development. Studies with an
Ire1 reporter mouse revealed that Ire1 is constitutively active in the pancreas and muscles
of adult animals [138], arguing that it contributes to the normal physiology of these
organs. Disruption of the Ire1 gene in mice results in embryonic lethality after 12.5 days
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of gestation [19, 139, 140], demonstrating that it has an essential function early in mouse
development. In vivo imaging analysis found that indeed Ire1 is highly activated in the
placenta of embryos. More high-resolution studies revealed that loss of Ire1 resulted in a
severely dysfunctional labyrinth layer of the placenta [139], which is normally highly
vascularized and is the site of nutrient and oxygen exchange between the mother and
fetus. The placenta phenotype in the Ire1 null mice correlated with a significant decrease
in VEGFA expression in this tissue, which was independent of HIF signaling, as HIF
protein levels were unchanged between the wild-type and null embryos. To confirm that
the early embryonic lethality in the Ire1 null mice was due to inadequate placenta
vascularization, mice in which the Ire1 gene had been floxed were crossed with Mox2+/Cre
transgenic mice [139]. Mox2 is ubiquitously expressed in all tissues except in the
labyrinthine trophoblasts of the placenta, thus allowing Ire1 null embryos to be produced
that have normal levels of Ire1 in the placenta. This strategy rescued the embryonic
lethality observed in the conventional Ire1 null mice and the placentas in the rescued
mice were well vascularized. Since the UPR is the only known mechanism for activating
Ire1, these data argue that the UPR plays a critical role in embryonic development and
survival by controlling angiogenesis. In addition to the role of the UPR in regulating
placental angiogenesis, its activation has been detected in highly vascularized normal
tissues like the human endometrium. Expression of BiP, the master regulator of the UPR
is significantly induced in the early proliferative and late secretory phases of the
menstrual cycle [141]. Although the function of this induction has not been investigated,
it is reasonable to hypothesize that the UPR also plays a role in the regulation of
angiogenesis in this tissue. Although angiogenesis is known to be critical in wound
healing [142], there are currently no studies to determine if the UPR plays a role in this
process.
Identifying the UPR-Induced Transcription Factor that Up-Regulates VEGFA has
not been Straightforward
In spite of a number of recent studies implicating the UPR in VEGF regulation,
identifying the responsible transcription factor(s) has been contradictory. Although the
mouse genetic studies, strongly implicated Ire1 in regulating VEGF in the placenta, they
argued that this was not via XBP-1. Examining placenta in mice that were deficient in
XBP-1 revealed only mild morphological and histological phenotypes [139]. There was
no obvious explanation for this finding as XBP-1 has long been considered to be the only
known target of Ire1’s activity. Indeed, studies from the Urano lab [121] and ours [49]
demonstrated direct binding of XBP-1 to the VEGF promoter in humans and mice, which
results in an increase in VEGF mRNA in human HepG2 and mouse MEFs respectively.
A separate study injected transformed XBP-1 deficient MEFs into the flacks of SCID
mice [44]. The resulting tumors were much smaller than the wild-type controls, however
there was no description of the effects on vascularization. Cell culture experiments with
XBP-1 deficient MEFs using extreme hypoxia to activate the UPR showed no difference
in VEGF secretion compared to wild-type MEFs [44]. This might be interpreted to be
supportive of the placenta data, however it is critical to note that extreme hypoxia would
also activate the HIF pathway, which of course would up-regulate HIF. Two others
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studies led further support to Ire1 playing a role in regulating VEGFA in a tumor model
[42, 43]. In both cases a dominant negative construct of Ire1 were expressed in the U87
human glioma tumor line. Orthotopic studies revealed reduced growth and
vascularization of tumors, which was linked to decreased VEGFA, as well as other
proangiogenic factors [42]. From these studies, one might conclude that Ire1, perhaps
independent of XBP-1, is a major regulator of VEGF.
However, the importance of ATF4 in regulating VEGF expression was suggested
in cell culture studies by Roybal et. al. using ATF4 null MEFs. Several thiol-containing
reductive compounds, as well as thapsigargin, were shown to activate the UPR and
transcriptionally up-regulate VEGF mRNA via an ATF4-dependent mechanism [143].
However, similar to our studies, the level of VEGF induction with these stresses was very
modest, which we found was due to a particularly high basal level of transcription in
these particular cells [49], making it difficult to assess the contribution of ATF4 using
knockout MEFs. Two other studies supported the role of ATF4 in regulating VEGF
expression. In the first case cells were treated with oxidized phospholipids, a common
lipid component of atheroma that was shown to induce ER stress. They demonstrated
direct binding of ATF4 to the human VEGF promoter in human HUVEC and HAEC cells
after treatment with oxidized phospholipids and demonstrated ~50% reduction in VEGF
mRNA when ATF4 levels were reduced with siRNA [103]. The second study use siRNA
to reduce ATF4 levels in human HepG2 cells and found a similar reduction in VEGF
transcripts [121]. These data are in keeping with our studies in two neuroblastoma cell
lines where we observed an even greater reduction (~ 90%) in the VEGF transcription
rate and VEGF secretion using siRNA to VEGFA (Chapter 3). It is unclear if the
differences in the effects on VEGF are due to variability in the efficiency of ATF4
depletion or to the cell types used. Two studies [49, 121], ours included, examined
whether ATF6 might also contribute to ER stress induced VEGF up-regulation as there
are putative ATF6 binding sites on the VEGF promoter, but the effects of this
transcription factor appear to be quite modest.
Thus on face value, it would seem that there are contradictory data to demonstrate
a significant, and in cases sole, contribution of a single UPR component in regulating
VEGF transcription; Ire1 and ATF4. Importantly ATF4 is downstream of the PERK arm
of the UPR not the Ire1 arm. Although these branches are thought to signal
independently of each other it is feasible that there is some interplay between them. For
example, most recently an XBP-1-independent activity for Ire1 has been identified. In
addition to cleaving XBP-1 mRNA, Ire1 was shown to have a rather promiscuous RNase
activity, known as Regulated Ire1-dependent decay of messenger RNA (RIDD), which
serves to more globally reduce the expression of RNA transcripts [144]. Although this
has not been directly examined, it could impact other branches of the UPR. Alternatively
it is possible that distinct UPR components or combinations of them are dominant in
different tissues or cell types.
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Why should angiogenic factor(s) be a target of the UPR?
A major function of the UPR in cell culture and in vivo, is thought to be restoring
or maintaining ER homeostasis in response to an inadequate or toxic environment that
adversely affects this organelle and its ability to fold and assemble proteins. Thus it is
perhaps not surprising that one mechanism for taking care of this problem in vivo would
be to increase the supply of blood flow to the affected cells so that more nutrients and
oxygen can be delivered and waste and other toxic products could be taken away. In
keeping with this possibility, physiological processes like wound healing require
increased vascularization, and studies show evidence of UPR activation in the affected
cells. Although a major focus of my studies and other recent ones was on VEGF, it is
important to emphasize that our microarray data revealed a 2-fold or greater upregulation of 13/19 genes that are positive regulators of angiogenesis. In addition to
VEGF, the transcriptional up-regulation of three of these, angiogenin, FGF-2, IL-8 was
confirmed in a variety of cell lines representing different tissues and species using several
UPR inducers [49]. The balance in angiogenesis is tightly regulated by both
proangiogenic and antiangiogenic factors, and interestingly we found that one antiangiogenic factor, vasohibin, was down regulated. Another recent study found several
other antiangiogenic factors like SPARC, decorin and TIMP-2 to be up-regulated when
Ire1 activity was inhibited in a human glioma cell line [42].
However, since inadequate vascularization leads to decreased oxygen in tissues,
which would induce the HIF pathway, a potent inducer of VEGF, it is reasonable to ask
why this isn’t sufficient to regulate angiogenesis. Perhaps the first reason comes from the
fact that the UPR appears to regulate a multitude of proangiogenic factors, whereas the
HIF pathway is more focused on VEGF. Although VEGF is apparently the most potent
inducer of angiogenesis, in studies where VEGF inhibitors were used therapeutically,
treatment failure was linked to increased expression of the fibroblast growth factor family
members [145], which we have shown is a target of the UPR. Thus the ability to regulate
so many factors may provide a benefit to the UPR having this capability. A second
reason may stem from the stimuli that activate these pathways. Whereas the HIF
pathway is uniquely regulated by decreased oxygen availability, the UPR is induced by
low glucose levels, decreased pH, some heavy metals, and even by extreme hypoxia
giving it a broader number of potentially toxic conditions to respond to in which
increased blood flow might benefit the cells. While all of these conditions have the
potential to damage the cell, there is another UPR inducer with less toxic characteristics.
Studies have shown that the UPR can be activated in response to the increased trafficking
of proteins through the ER. This can be observed in the secretory tissues, like the
pancreas, liver and plasma cells, where activation of the UPR increases the capacity of
these cells to synthesize large quantities of proteins. This latter inducer of the UPR might
be particularly important in tissues like the placenta. The placenta must be highly
vascularized in order to supply adequate quantities of oxygen and nutrients to the
developing fetus and to remove toxic waste products. Since HIF1α protein is stabilized
only in response to limiting levels of oxygen, the ability to vascularize this tissue via the
HIF pathway would result in intermittent periods of low oxygen in the placenta, which
could be quite deleterious to the developing fetus. Indeed, the highly vascularized
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placenta does not have any detectable levels of HIF1α protein but instead shows strong
evidence of UPR activation. This suggests that the cues to activate angiogenesis in this
tissue might be less dependent on an inadequate microenvironment but instead rely on the
high secretory nature of the placenta. This raises an important point of how normal
physiological processes like angiogenesis can be controlled by alternate compensatory
pathways in different organs or cell types. This aspect of the UPR in regulating
angiogenesis in a HIF-independent manner might also be used in pathological conditions
like cancer, and ischemia to stimulate angiogenesis, as in both cases there is evidence of
UPR activation.
Does the UPR contribute to angiogenesis in tumor cells that also activate HIF?
In contrast to normal differentiated cells that rely on mitochondrial oxidative
phosphorylation to produce energy for most cellular processes, cancer cells rely on
glycolysis, a phenomenon known as the “Warburg effect”. The reason for cancer cells to
shift to a more inefficient method for producing energy is still under investigation but
some studies suggest that this facilitates the production of nucleotides and other
metabolic intermediates that are conducive to cell proliferation. A hypoxic environment
stabilizes HIF, which significantly contributes to the conversion of glucose to lactate, the
end product of glycolysis. Adaptation to the tumor microenvironment results in increased
glucose uptake and lactate production. However, the tumor microenvironment often
encounters decreased nutrients and glucose supply in addition to hypoxia. Thus, it is
important to assess the contribution of other pathways like the UPR to tumor cell
metabolism.
Studies are required to determine the percent of cells in a tumor that activate the
UPR and HIF signaling pathways alone and the percent that activate both pathways
simultaneously. Our studies show that activation of both pathways together are potent
inducers of VEGF expression compared to when each pathway is activated alone. Thus
identifying the expression profile of these pathways in tumors will be important. The
mechanism of how these two pathways influence each other to potently induce VEGF
expression is still unknown. It is possible that the UPR could enhance the activity of HIF
by yet unknown post-transcriptional mechanisms. The UPR could also have the ability to
enhance binding of HIF to its target genes like VEGF, by modifying the chromatin
structure and making it more accessible for HIF transcriptional machinery to bind and
transactivate its target genes.
Studies from our lab show that the UPR is activated throughout the tumor tissue,
this is largely due to the rapid proliferation and high metabolic rate of tumor cells. Thus,
areas that do not have the HIF pathway activated could still have the UPR activated with
subsequent activation of downstream transcription factors like ATF4. We would thus
expect ATF4 to be a critical regulator of VEGF expression in most parts of the tumor.
The follow up studies for this project in the orthotopic neuroblastoma tumor model will
enable us to determine the contribution of the UPR-inducible transcription factor ATF4 in
regulating tumor angiogenesis during different stages of tumor growth. The
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Dox-inducible regulation of ATF4 will give us the flexibility to turn off its expression
during early and late stages of tumor development. In this way we can determine the
relative importance of the UPR and HIF signaling in regulating tumor angiogenesis and
thus identify a druggable target for inhibiting angiogenesis.
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APPENDIX. SUPPLEMENTAL FIGURES FOR CHAPTER 2

Figure A-1. HIF signaling pathways are not activated by UPR inducers nor are
UPR targets activated by hypoxia. C6 cells were treated with 100 µM CoCl2, 1% O2
hypoxia (Hy), 2.5 µg/ml tunicamycin (Tm), 1 µM thapsigargin (Tg), or no glucose media
(No Glu) for 24 hours. Western blot analysis was performed to measure (A) BNIP3 and
CHOP protein levels in the cytosolic fraction. Hsc70 was used as a loading control. (B)
HIF1α levels were determined in the nuclear fraction using Lamin B1 as control and
CHOP levels were determined in the cytosolic fraction using Hsc70 as control.
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Figure A-2. UPR inducing agents up-regulate CHOP and BiP mRNA. Daoy, C6,
NB1691, SKNAS and NIH3T3 cells were treated with 100 µM CoCl2, 1% O2 hypoxia
(Hy), 2.5 µg/ml tunicamycin (Tm), 1 µM thapsigargin (Tg), or no glucose media (No
Glu) for 24 hours. RNA was extracted for qRT-PCR analysis and expression levels of
CHOP mRNA (black bars) and BiP mRNA (white bars) were determined relative to
18SrRNA. Experiments were performed in triplicate (values are mean ± SD).
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Figure A-3. Basal levels of proangiogenic factor expression in different cell lines.
Daoy, NB1691, SKNAS, C6 and NIH3T3 cells were treated with 100 µM CoCl2, 1% O2
hypoxia (Hy), 2.5 µg/ml tunicamycin (Tm), 1 µM thapsigargin (Tg), or no glucose media
(No Glu) for 24 hours. RNA was extracted for qRT-PCR analysis and basal levels of
expression for (A) VEGF (B) angiogenin (C) FGF2 and (D) IL-8 were determined
relative to 18SrRNA. Experiments were performed in triplicate (values are mean ± SD).

97

Figure A-4. Potential binding sites of UPR downstream transcription factors in
human, mouse and rat VEGF promoter. Two online softwares, rVista and
TRANSFAC were used to screen potential binding sequences of transcription factors,
XBP-1 (cyan), ATF4 (green), HIF (red) and ATF6 (yellow) in 9k upstream promoter
region of human, mouse and rat VEGF gene.
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Figure A-5. Basal levels of VEGF hnRNA in XBP-1 wild-type and null MEFs.
XBP-1 wild-type MEFs (black) and null MEFs (white) were untreated (NT),
Thapsigargin-treated (1µM), treated with media lacking glucose (No Glu) or
Homocysteine-treated (HCys, 10mM) for 8h and 14h. Total RNA from the indicated
samples was subjected to qRT-PCR and VEGF hnRNA/18S ratios were determined
relative to the control untreated samples.
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Figure A-6. ATF4 does not appear to bind to the rat VEGF promoter. (A)
Potential ATF4 sites in the rat VEGF promoter. (B) Cross-linked chromatin from C6 cells
that were untreated (NT), Thapsigargin-treated (Tg), or incubated in No glucose media
(No Glu) for 8h were immunoprecipitated with anti-ATF4. As positive control, primers
spanning the ATF4 binding region on the CHOP promoter were used to PCR amplify the
anti-ATF4 precipitated chromatin (C) CHOP protein levels were determined using
Western blot analysis in the C6 cells that were used in the ChIP assays.
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